CD146, and use thereof in diagnosis of fibrosis as biomarker and use thereof in treatment of fibrosis as therapeutic target
CD146 is used as a biomarker and therapeutic target to diagnose and treat fibrosis, offering effective monitoring and potential reversal of fibrotic processes in cardiac, renal, skin, and pulmonary tissues.
Patent Information
- Application Number
- JP2024125701
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-09-26
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-06
AI Technical Summary
Current treatments for fibrosis, particularly cardiac and renal fibrosis, are limited in effectiveness, and there is a lack of reliable biomarkers for early detection and monitoring, leading to inadequate preventive and therapeutic strategies.
CD146, specifically its soluble form (sCD146), is utilized as a biomarker for diagnosing and monitoring fibrosis, and as a therapeutic target for treating fibrosis through inhibitors and antibodies targeting CD146 proteins.
CD146 serves as an effective biomarker for early detection and monitoring of fibrosis, and its inhibitors can potentially reverse or prevent fibrotic processes in cardiac, renal, skin, and pulmonary tissues.
Smart Images

Figure 2024156834000008 
Figure 2024156834000009 
Figure 2024156834000010
Abstract
Description
[Technical field]
[0001] [Field of the Invention] The present invention relates to the field of medicine, in particular to the field of diagnosis and treatment of fibrotic diseases. The present invention relates to CD146 and its use as a biomarker in the diagnosis of fibrosis. The present invention also relates to the use of fibrosis as a therapeutic target. Also provided are compositions and methods for detecting a predisposition to fibrosis in a subject, diagnosing fibrosis in a subject, The present invention also relates to compositions and methods for predicting and / or monitoring fibrosis in a subject. and a compound comprising a CD146 inhibitor for use in the prevention or treatment of The present invention relates to compositions, kits of compositions and their use in diagnostic or therapeutic settings. [Background technology]
[0002] Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue during a repair or reaction process. Physiologically, fibrosis acts to deposit connective tissue, which The tissue can obliterate the structure and function of the underlying organ or tissue. Fibrosis is defined as the pathological accumulation of extracellular matrix (ECM) proteins in the affected tissues. This results in scarring and thickening of tissue, which essentially interferes with normal organ function. It is an exaggerated wound healing response. The tissue becomes increasingly stiff and loses its functionality.
[0003] Fibrosis is similar to the scarring process, in that both involve collagen and glycosaminoglycans. The process involves the stimulation of fibroblasts, which underlie the connective tissue, including the myocardium. It is initiated when immune cells such as phages release soluble factors that stimulate fibroblasts. The best-characterized profibrotic mediator is transforming growth factor β, The growth factor beta binds to macrophages and any damaged tissue between the surface, called the interstitium. Other known soluble mediators of fibrosis include CTGF, platelet-derived These include PDGF, interleukin 4 (IL-4), and autoimmune diseases. This process of tissue repair is complex and involves ECM synthesis and Tight control of degradation ensures the maintenance of normal tissue architecture. However, the entire process is necessarily However, in cases where tissue injury is severe or recurring or where wound healing is delayed, If the response itself becomes deregulated, this may lead to a gradually irreversible fibrotic response. There is.
[0004] Fibrosis occurs in organs and many tissues in the body, typically as a result of inflammation or injury. Possible causes include, for example, cardiac (atrial fibrosis, endomyocardial fibrosis, infarction, in particular Previous myocardial infarction), kidneys (renal fibrosis), liver (cirrhosis, biliary atresia), lungs (progressive pulmonary edema) fibrosis), brain (glial scarring), arteries (arteriosclerosis), knee or shoulder joints (arthrofibrosis), intestines ( Crohn's disease), hands and fingers (Dupuytren's contracture), skin (keloids, nephrogenic systemic fibrosis) , soft tissue of the mediastinum (mediastinal fibrosis), soft tissue of the bone marrow (retroperitoneal fibrosis), bone marrow (myelofibrosis), etc. Includes:
[0005] Glomerular disease can gradually or rapidly lead to renal fibrosis and chronic kidney disease (CKD). Rapidly progressive or crescentic glomerulonephritis (GN) is characterized by glomerular damage and the development of crescents. It is a group of rare kidney diseases that can rapidly progress to end-stage renal failure as a result of significant inflammation accompanied by (Mathieson, P, 2007). Other renal compartments are affected, and renal The functional consequences of such structural lesions include ductular formation and inflammation leading to interstitial fibrosis. is the rapid deterioration of renal function (Moeller, MJ 2013). Even so, given that pathophysiological progress has been made in the main in preclinical models of experimental GN, Both the inflammatory process and the resulting fibrosis play a role in the control and progression of the disease. Molecular insight into the mechanism of disease is still limited, and current treatments remain only partially effective. There is none.
[0006] Cardiac fibrosis may be a response to certain forms of heart disease, such as myocardial infarction, certain cardiomyopathies, or hypertension. The wound healing process is accompanied by the expression of extracellular matrix proteins (fibronectin, collagen, collagenase, collagenase complex, collagenase complex). The lesions are characterized by increased deposition of collagen I and III, which is involved in the decomposition of the matrix. This is accompanied by a decrease in the expression of metalloproteinases (MMPs) that contribute to This tissue accumulation enhances the intrinsic cardiac function as well as the ability to contract and relax. Increased stiffness and compliance of the damaged heart, which loses its ability to generate electrical activity All these changes lead to a decrease in the rate at which the heart can function. Over a long period of time, this can lead to cardiac arrest (Chaturvedi et al., 2010).
[0007] Cardiac fibrosis is classified into two types based on its location within the myocardium. - "Reactive / Interstitial" fibrosis, which corresponds to the progression of fibrosis into the interstitial spaces between cardiomyocytes. Type fibrosis has been described in more detail in relation to aging (Chen and Francis, Ogiannis, 2010; Mays et al., 1991). Indeed, many studies have shown that The increase in myocardial collagen density was associated with a decrease in the total number of cardiomyocytes leading to hypertrophy and a significant increase in myocardial collagen deposition. These changes can lead to diastolic dysfunction while preserving systolic function. This causes a decrease in cardiac compliance leading to gogiannis, 2011). - "Reparative fibrosis" is a condition that causes heart disease such as myocardial infarction. This refers to the formation of scar tissue in response to injury (Weber, 1989).
[0008] Currently, there are few effective treatments to control the deleterious process of cardiac fibrosis. Therefore, the search for new treatments to halt or reverse this process is a major public health challenge.
[0009] The frequency of lesions with fibrosis is associated with aging and the presence of risk factors for cardiovascular disease (diabetes, obesity, and hypertension). To date, no specific biomarkers have been used to detect fibrosis. The only way to quantify fibrosis is by biopsy. There are no treatments available for the treatment of fibrosis, particularly those that can reverse the fibrotic process. do not have.
[0010] Diagnosing and monitoring fibrosis or determining whether a patient is at risk for developing fibrosis Simple, reliable and specific tests that can be used to maintain or improve the health of patients are still lacking. It would be highly valuable to rapidly develop preventive and treatment strategies aimed at reducing the risk of infection. , is the object of the present invention. [Prior art documents] [Non-patent literature]
[0011] [Non-Patent Document 1] Alais , S , Allioli , N , Pujades , C , Duband , JL , Vainio , O , Imhof , BA , Dunon , D. HEMCAM / CD146 downregulates cell surface expression of beta1 integrins . Journal of cell science114:1847–1859 (2001)
Outdoor Tool2
Outdoor Tools3
Outdoor Tools 4
Direct Environment 5
Outdoor Configuration6
Direct Environment 7
Outdoor Track 8
Outdoor Tools9
Outdoor Tools 10
Outdoor Content11
Outdoor Tools 12
Outdoor Content13
Outdoor Tools 14
Outdoor Tools 15
Outdoor Content 16
Outdoor Track 17
Outdoor Tools 18
Outdoor Tools 19
Outdoor Tools20
Direct Environment21
Optional Website22
Optional Trademark23
Optional Trademark24
Direct Entries 25
Direct Entries 26
Direct Accounts 27
Non-Patent Document 28
Non-Patent Document 29
Non-Patent Document 30
Table 31
Table 32
Wood 33
Direct Entries 34
Direct Entries 35
Direct Entries 36
Direct Entries 37
Direct Entries 38
Direct Entries 39
Outdoor Track 40
Optional Trademark41
Outdoor Tools 42
Direct Environment 43
Direct Environment 44
Direct Environment 45
Direct Entries 46
Direct Entries 47
Direct Environment 48
Outdoor Track 49
Outdoor Track50
Direct Entries51
Outdoor Track52
Direct Entries53
Direct Entries 57
Direct Entries 58
Outdoor Track59
Direct Entries 60
Direct Entries 61
Direct Environment 62
Direct Entries 63
Non-Patent Document 64
Non-Patent Document 65
Direct Entries 66
Direct Entries 67
Direct Entries 68
Direct Entries 69
Outdoor Track 70
Outdoor Track 71
Direct Environment 72
Outdoor Track 73
Direct Entries 74
Free Trademark 75
Direct Entries 76
Direct Environment 77
Non-Patent Document 78
Non-Patent Document 79
Non-Patent Document 80
Summary of the Invention
Problems to be Solved by the Invention
[0012] The present inventors herein report for the first time the use of CD146 in the diagnosis of fibrosis, These are interesting biomarkers and potentially useful therapeutic targets in the treatment of fibrosis. This makes it clear that it is a therapeutic tool. [Means for solving the problem]
[0013] CD146 protein, in particular, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, Soluble CD146 (sCD146) selected from sequence number 5, sequence number 6 and sequence number 7 or the I5-13 soluble CD146 protein of SEQ ID NO: 8, or the I5-13 soluble CD146 protein of SEQ ID NO: 9 I10 soluble CD146 protein, typically as a biomarker, The present invention relates to a method for detecting, diagnosing and / or preventing a predisposition to fibrosis, particularly of the heart, kidney, skin and / or lung. or soluble CD146 (sCD146) for use in predicting or monitoring disease progression. 146) The proteins described herein.
[0014] Further described herein are methods for administering the invention to a subject, whether in vitro, ex vivo or in vivo. Detecting or determining a predisposition of a subject to fibrosis in the liver, particularly cardiac, renal, skin or lung fibrosis. The method is typically a method for diagnosing and / or prognosticating a disease or condition. The expression level of CD146 protein in the pool, typically soluble CD146 protein, The expression level of the protein, in particular, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5. Expression level of soluble CD146 protein selected from SEQ ID NO:6 and SEQ ID NO:7 , I5-13 of SEQ ID NO: 8 or I of SEQ ID NO: 9 10. Determining the expression level of soluble CD146 protein.
[0015] Further described herein are methods for administering the invention to a subject, whether in vitro, ex vivo or in vivo. The present invention relates to a method for monitoring fibrosis in a subject, preferably cardiac or renal fibrosis. Typically, CD146 protein expression levels are measured in a subject's biological sample at two or more time points. determining the expression level of the soluble CD146 protein, The CD146 protein is represented by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, No. 5, SEQ ID NO: 6 and SEQ ID NO: 7; and At a later time point in the subject's biological sample, A higher value compared to the baseline value obtained at the time point indicates increased fibrosis in the subject, whereas a higher value indicates increased Lower soluble CD146 protein levels indicate reduced fibrosis, whereas equal soluble CD The 146 protein level indicates that fibrosis is not progressing in the subject.
[0016] Further described herein are methods for detecting and determining whether a subject's fibers are in vitro, in vivo, or ex vivo. A method for monitoring fibrosis, particularly skin or lung fibrosis, comprising administering to a subject an antibody of SEQ ID NO: 8 5-13. Determine the expression level of soluble CD146 protein in two or more biological samples of the subject. determining the expression level of soluble CD146 protein at the time point above, In the body sample at a later time point, the baseline value obtained in the subject's body sample at an earlier time point was compared with In comparison, a high level indicates increased fibrosis in the subject, whereas a high level of human soluble CD14 Lower levels of CD6 protein indicate reduced fibrosis and are equivalent to human soluble CD146 The levels of the protein indicate that fibrosis is not progressing in the subject.
[0017] Further described herein are methods for detecting and determining whether a subject's fibers are in vitro, ex vivo, or in vivo. A method for monitoring fibrosis, particularly skin or lung fibrosis, comprising administering to the patient an I10 soluble C The expression level of D146 protein is determined in a biological sample from the subject at two or more time points. determining an expression level of soluble CD146 protein in a biological sample from the subject; , at later time points, the subject's biological sample shows a lower The lack of human soluble CD146 protein indicates increased fibrosis in the subjects. Higher levels indicate reduced fibrosis, while lower levels of human soluble CD146 protein Higher levels indicate reduced fibrosis, and levels of human soluble CD146 protein Equality indicates that fibrosis is not progressing in the subject.
[0018] Further described herein are CD146 inhibitors, in particular SEQ ID NO:1, SEQ ID NO:2, A soluble form selected from SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 CD146 protein, which is isolated from a subject, typically a fibrinogen, by the methods described herein. having a predisposition to fibrosis, being affected by fibrosis, having incomplete fibrosis, fibrosis In subjects identified as having increased or poor prognosis fibrosis, , in particular, soluble CD146 protein for use in the prevention or treatment of cardiac and / or renal fibrosis - Patents.com It is.
[0019] Further described herein are CD146 inhibitors, in particular I5-13 of SEQ ID NO:8. An inhibitor of soluble CD146 protein, which is capable of inducing a subject, typically a subject as described herein. The method allows the identification of patients with a predisposition to fibrosis, those affected by fibrosis, and those with non-advanced fibrosis. In subjects identified as having fibrosis, increased fibrosis, or poor prognosis fibrosis, A soluble CD1 for use in the prevention or treatment of fibrosis, particularly skin or lung fibrosis, 46 proteins.
[0020] Further described herein are CD146 inhibitors, in particular those represented by SEQ ID NO:1, SEQ ID NO:2, A soluble form selected from SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 CD146 protein inhibitor or I5-13 soluble CD146 protein of SEQ ID NO: 8 The inhibitors can be administered in vitro or ex vivo to treat fibrosis, particularly cardiac fibrosis, in a subject in need thereof. For use in preparing a composition for preventing or treating liver and / or kidney fibrosis. The purpose is to use
[0021] The present inventors herein provide CD146 inhibitors, in particular those represented by SEQ ID NO: 1, SEQ ID NO: 2 , SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7 Inhibitor of 146 inhibitor protein or I5-13 soluble CD146 protein of SEQ ID NO: 8 and the treatment of fibrosis in a subject, particularly cardiac, renal, skin and / or pulmonary fibrosis. Also provided are compositions comprising a pharma- ceutically acceptable carrier for use in the prophylaxis or treatment of diseases. Provide.
[0022] Further described herein are CD146 proteins, in particular those represented by SEQ ID NO:1, SEQ ID NO:2, 2. A sequence selected from SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7. Soluble CD146 protein or I10 soluble CD146 protein of SEQ ID NO: 9, and For use in the prevention or treatment of skin fibrosis and / or pulmonary fibrosis in elephants, preferably in humans. and a pharma- ceutically acceptable carrier.
[0023] The inventors also provide herein antibodies and fragments which Proteins, in particular, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, No. 6 and SEQ ID NO: 7, I5-1 of SEQ ID NO: 8 3. Soluble CD146 protein or I10 soluble CD146 protein of SEQ ID NO: 9 The present invention describes antibodies and fragments that can be used in the present invention. The fragments include the heavy chain variable regions (V H) CDR polypeptide sequences and the light chain variable domains of SEQ ID NO: 97, sequence FAS and SEQ ID NO: 98 Another antibody newly described herein comprises a VL domain (VL) CDR polypeptide sequence. Heavy chain variable region (VH) CDR polypeptides of SEQ ID NO: 87, SEQ ID NO: 88 and SEQ ID NO: 89 and the light chain variable region (VL) CDR sequences of SEQ ID NO: 90, sequence FAS and SEQ ID NO: 91. and a polypeptide sequence thereof.
[0024] The present inventors further provide herein a method for treating fibrosis, particularly cardiac or renal fibrosis. The present invention describes a method for diagnosing a mutated genomic DNA in a subject's biological sample. The method typically comprises detecting, in a biological sample from a subject, Typically, in the serum of a subject, SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, CD146, preferably sCD14, selected from sequence number 5, SEQ ID NO: 6 and SEQ ID NO: 7 Such a method includes a step of detecting, preferably quantifying, the amount of the 6 protein. Typically, as described herein, the CD146 protein, preferably sCD This involves using an antibody that binds the 146 protein.
[0025] The inventors also provide herein a method for treating fibrosis, in particular cardiac, renal, skin and / or pulmonary fibrosis. to treat fibrosis in a subject in need thereof, typically by the methods described herein. predisposed to fibrosis, affected by fibrosis, with incomplete fibrosis, with increased fibrosis and treating subjects identified as having large or poor prognosis fibrosis. The method is typically carried out using SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: No. 4, SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7, in particular Inhibitor of soluble CD146 inhibitor protein or I5-13 soluble of SEQ ID NO: 8 Inhibitors of CD146 inhibitor proteins, or compounds containing such CD146 inhibitors This involves administering a composition, typically an effective amount, to the subject.
[0026] In vitro, ex vivo or in vivo, an agent, typically SEQ ID NO: 1, SEQ ID NO: 2, CD1 selected from SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 46 inhibitors, in particular soluble CD146 inhibitor proteins or SEQ ID NO: 8, an inhibitor of the I5-13 soluble CD146 inhibitor protein, or fibrosis, in particular A method for monitoring the effectiveness of a composition for treating cardiac, renal, skin and / or pulmonary fibrosis also includes The method includes detecting CD146, typically a marker for CD146 expression, in a first biological sample from a subject. The expression of soluble CD146 may be measured by administering to the subject, prior to any treatment of fibrosis, an agent or composition for the treatment of fibrosis. CD146, typically soluble CD146, in a second biological sample from the same subject exposed to The method typically includes a step of comparing the expression of 146 with that of 146.
[0027] In another aspect, the present disclosure provides a method for producing a product, typically a protein, as described herein. Kits containing any one or more of the inhibitors or compositions of CD146 (soluble form) are provided. The kit also includes instructions for using the protein, inhibitor, or composition according to the disclosed methods. . [Brief description of the drawings]
[0028] [Figure 1] Figure 1 shows that CD146 is induced in experimental GN in mice. CD146 is highly upregulated in kidneys that are gradually damaged from day 4 to day 15 after administration of NTS (decomplemented nephrotoxic serum) to mice, and is mainly localized in damaged glomeruli (A). This upregulation was confirmed by Western blot (B, C). *, P<0.05, **, P<0.01, ***, P<0.001. Magnification of microscopic image: ×200. [Diagram 2] Figure 2 shows that CD146 knockout mice are protected from NTS-induced glomerulonephritis. Body weight is increased in mice after induction of disease (A). Renal function was assessed by proteinuria and expressed as creatinine (B), blood urea nitrogen (C) grams of protein / mmol. All three parameters reveal a slower progression of disease in CD146 knockout mice. Masson's trichrome staining of kidney slices shows that kidney structure is preserved in CD146 knockouts, with less expression of glomerular crescents (E) and tubular dilations (F). Crescents are expressed as the percentage (%) of glomeruli exhibiting cellular crescents. *, P<0.05, **, P<0.01. Magnification of microscopic images: ×200. [Diagram 3]Figure 3 shows that CD146 knockout mice have reduced expression of kidney inflammation and fibrosis. QPCR for I1-1β (A), TNF-α (B) and ICAM-1 (C) showed that inflammatory responses were limited in the kidneys of CD146KO mice 15 days after induction of NTS-GN. Immunohistochemistry for F4 / 80 (D,E) and CD3 (F,G) confirmed that adhesion of monocytes and lymphocytes was limited in CD146KO mice, respectively. At the same time points, QPCR for quantification of TGFβ (H), collagen III (I) and Sirius red staining (J) showed that fibrotic responses were limited in CD146KO mice. *,P<0.05,**,P<0.01,***,P<0.001. Enlarged microscopic images: ×200. [Figure 4] Figure 4 shows that CD146 is strongly induced in glomerular endothelial cells after NTS administration. Double immunofluorescein kidney cortical slices for CD146 and various markers of glomerular components such as endothelial cells (CD31 / PECAM1) (A), podocytes (Nestin) (B), parietal (Claudin-1) (C) and mesangial cells (α-SMA) (D) showed that CD146 expression was mainly induced in glomerular endothelial cells. Magnification of microscopic image: ×400. [Diagram 5]Figure 5 shows the generation of CD146-EC-del mice. CD146-flox mice were first crossed with B6.Cg-Gt(ROSA)26Sortm6(CAG-ZsGreen1)Hze / J mice (Jackson laboratories), which express the fluorescent protein ZsGreen1 as a reporter for Cre recombinase activation. Mice with endothelial cell-specific deletion of the CD146 gene were then generated by further crossing CD146flox-Zs Green animals with the Cdh5(PAC)-CreERT2 mouse line established by Ralf Adams (A). Deletion of the CD146 gene was induced by intraperitoneal injection of tamoxifen diluted in corn oil (10 mg / ml solution, 1 mg tamoxifen / injection) and administered for three consecutive days. Immunofluorescence for CD146 confirmed deletion from the vascular endothelium (B). Accordingly, CD146 mRNA expression was also decreased in the kidneys of CD146-EC-del mice (C). *, P<0.05; **, P<0.01; #, P=0.05 (NTS vs. CTL). Magnification of microscopic images: ×200. [Figure 6] Figure 6 shows that endothelium-specific deletion of CD146 protected kidney function and structure after induction of NTS-GN. NTS-induced increases in body weight (A), proteinuria (B), and BUN (C) were all blunted in CD146-EC-del mice. Furthermore, Masson's trichrome staining (D) in kidney cortical slices revealed that glomerular crescents (E) and tubular dilation (F) were reduced 15 days after NTS injection. *, P < 0.05; **, P < 0.01 (NTS vs. CD146-EC-del); #, P < 0.05; ##, P < 0.01 (NTS vs. CTL-PBS). Magnification of microscopic images: ×200. [Figure 7]Figure 7 shows that CD146 endothelial-specific deletion protected mice from inflammation and renal interstitial fibrosis. F4 / 80 staining shows that monocyte infiltration was blunted in CD146-EC-del mice 15 days after NTS injection (A). Thus, QPCR for VCAM-1 (B) and MCP-1 (C) shows that upregulation of this inflammatory marker was blunted. Furthermore, QPCR for TGF-β1 (D) and Colla1 (E) showed similar results. *, P<0.05; **, P<0.01. Magnification of microscopic images: ×200. [Figure 8] Figure 8 shows expression of CD146 transcripts in human glomerular diseases. Gene expression data from isolated glomeruli from patients with diabetic nephropathy (DN), minimal change nephrotic syndrome (MCD), IgA nephropathy (IgA), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MGN), lupus nephritis (SLE), rapidly progressive glomerulonephritis (RPGN), and controls (biopsy of graft tissue before transplantation). CD146 expression was significantly and differentially regulated in glomerulopathies compared to controls. [Figure 9] FIG. 9 shows the steps of myocardial infarction (A) and induction of cardiac fibrosis by a cell population giving rise to myofibroblasts (B). [Figure 10] Figure 10 shows a model of myocardial infarction. The left descending coronary artery is permanently ligated (A and B). The animals are sacrificed 21 days after the operation for various examinations (C). [Figure 11] Figure 11 shows the immunohistological principle and method. Indirect immunodetection of a protein of interest is performed with a single signal amplification system. In this method, the protein of interest present in the tissue is detected with a primary antibody. The hybridization of this antibody is detected by a secondary antibody bound to a biotin molecule. By adding an avidin-biotin complex bound to the enzyme horseradish peroxidase (HRP), the target antigen can be detected after deposition of a specific substrate (diaminobenzidine). The reaction produces a stable brown precipitate that can be observed by light microscopy (Tables 1 and 2). [Figure 12] FIG. 12 illustrates the principle of Western blotting. [Figure 13] FIG. 13 shows the location of cardiac fibrosis zones (A and B) and CD146 RNA expression (C) in "MI" (or "IM") animals (n=3). The infarcted / fibrotic zone or area ("IZ" or "IA" or "FZ" or "FA") is located in the left ventricular apex below the ligature. The border zone or area ("BZ" or "BA") is located immediately proximal to the infarcted zone, and the distal / remote zone or area ("DZ" or "DA" or "RZ" or "RA") is located above the ligation zone. Cardiac fibrosis (B, 60X objective) is located in the infarcted zone (red arrow) and has expanded into the border zone (blue arrow). [Figure 14] FIG. 14 shows CD146 / sCD146 expression in a myocardial infarction model (n=3). (A) CD146 immunodetection: Immunodetection of CD146 shows increased labeling in the ventricular wall of MI animals compared to sham animals. Fibrotic areas are not labeled ("IA") whereas surrounding cardiomyocytes are labeled ("BA"). Some images are taken with a 20X objective while others are taken with a 60X objective. (B) CD146 ELISA (n=2): CD146 concentrations were determined in serum of 2 sham and 2 MI mice. Results are shown in ng / ml. [Figure 15] Figure 15 shows CD146 expression in a model of age-related fibrosis (n=3). Sirius red staining (e) and CD146 immunodetection (f) of myocardial sections from 24 month old animals (e, f). [Figure 16] Figure 16 shows the role of CD146 in cardiac fibrosis throughout aging. Sirius red staining of cardiac fibrosis (a, b: 40X objective) and quantification of the fraction of area occupied by collagen (c) (n=3) (p=0.0001) in 24 month old females. A - RT-PCR quantification of collagen RNA expression (d) (n=1). B - Staining of cell membrane and quantification of cardiomyocyte size (n=3) (p<0.0001). [Figure 17]Figure 17 shows the role of CD146s in the acquisition of a myofibroblast phenotype. Cell proliferation studies (A) showed a comparable increase during stimulation with CD146s as observed with TGF-β (p<0.05). Expression of the myofibroblast marker SMA was increased after 48 h of stimulation with CD146 (50 ng / mL) in RNA analysis (B) and protein analysis (C), and actin fibers were lengthened comparable to stimulation with TGF-β (D) (20X objective). Expression of fibronectin and type I collagen (E) was also increased comparable after stimulation with TGF-β. CD146 induces an increase in the expression of TGF-β at the RNA level (F). [Figure 18] FIG. 18 shows a mouse model of treatment of UUO (unilateral ureteral obstruction) with renal failure and fibrosis with various doses of anti-sCD146 antibody. Male C57BL / 6 mice aged 8-12 weeks underwent ligation of the right ureter. The right ureter was exposed through a midline abdominal incision and completely occluded with a 5.0 silk ligature 1 cm below the renal pelvis. After surgery, four groups of seven animals were made. One group of animals served as a control and was treated with vehicle intravenously on days 1, 4, 7 and 10. One group of animals was treated with anti-sCD146 antibody intravenously at 10 micrograms per mouse on days 1, 4 and 10 after surgery. Another group of animals was treated with the same protocol, but only on days 7 and 10 after surgery. Finally, the last group of animals was treated with control IgG at 10 micrograms per animal IV on days 1, 4, 7 and 10 after surgery. [Figure 19] FIG. 19 shows the therapeutic effect of anti-sCD146 on renal fibrosis. 14 days after surgery, animals were sacrificed and kidneys were removed for immunohistochemistry. Fibrosis was estimated with Silas red in the experimental or contralateral kidney. The results show that fibrosis was increased in the experimental kidney compared to the contralateral kidney. Treatment with IgG did not alleviate fibrosis. In contrast, treatment with anti-sCD146 antibody for 1-14 days or 7-14 days significantly attenuated fibrosis. [Figure 20]FIG. 20 shows the therapeutic effect of anti-sCD146 antibody on alpha-SMA expression. 14 days after surgery, animals were sacrificed and kidneys were removed. Alpha-SMA expression was determined by immunohistochemistry using specific antibodies in experimental or contralateral kidneys. Results show that alpha-SMA was increased in experimental kidneys compared to contralateral kidneys. Treatment with IgG did not alleviate alpha-SMA expression. In contrast, treatment with anti-sCD146 antibody for 1-14 days or 7-14 days significantly attenuated alpha-SMA expression. [Figure 21] FIG. 21 shows the effect of proteinase inhibitors on the secretion of soluble CD146s in endothelial cells. A: The secretion of soluble CD146 (CD146s) was determined in ECFCs in response to a 24-h treatment with 20 ng / ml TNF, 20 ng / ml VEGF, 5 ng / ml TGFb, 50 ng / ml netrin, 50 ng / ml Wnt5a and 50 ng / ml Wnt3a. B: The effect of the pan-inhibitor GM6001 was tested by ELISA on CD146s secretion in ECFC cells. Experiments were performed in control conditions and after a 24-h treatment with 20 ng / ml TNF. The insert shows that TNF treatment significantly increases CD146s from 24 hours of treatment. A dose-dependent effect of GM6001 was exerted between 1 μM and 50 μM. Results are the mean + / - SEM of 5 experiments. C: The effect of furin convertase inhibitors (IF) was examined on CD146s secretion at 50 μMon after 24 h treatment with TNF 20 ng / ml in control conditions. Results are the mean values + / - SEM of 3 experiments. D: The effect of TIMP-1, -2 and -3 (1 μg / ml) was examined on CD146 secretion at 1 μg / ml after 24 h treatment with TNF 20 ng / ml in control conditions. Results are the mean values + / - SEM of 3 experiments. *: P<0.05, **: P<0.01, ***: P<0.001, experimental vs. control. [Figure 22]FIG. 22 shows that ADAM10 is involved in shedding of the long isoform of CD146 in ECFCs (human endothelial colony forming cells). A: ECFCs were transfected with siRNA targeting short (shCD146) or long (IgCD146) isoforms of CD146 and control siRNA. Soluble CD146 (sCD146) secretion was determined. Results are the mean + / - SEM of 4 experiments of each type. B: ECFCs were transfected with siRNA targeting MT1-MMP, MMP2, ADAM10 or Tace and control siRNA (C). Soluble CD146 (sCD146) secretion was determined. In one condition, cells were treated with GM6001 at 10 μM. Results are the mean + / - SEM of 5 experiments of each type. C: ADAM10 was immunoprecipitated in ECFCs cultured in basal conditions. Long (IgCD146) and short (shCD146) isoforms of CD146 were detected by Western blot using specific antibodies. Results are representative of three different experiments. D: ECFCs were transfected with siRNA targeting ADAM10 or Tace and control siRNA (C). Permeability of ECFC monolayers grown on semipermeable filters was determined using dextran-FITC. Results are the mean + / - SEM of three experiments. E: ECFCs were transfected with plasmid vectors encoding ADAM10 (p-ADAM10) or Tace (p-Tace) and a control plasmid vector. Permeability of ECFC monolayers grown on semipermeable filters was determined using dextran-FITC. Results are the mean + / - SEM of three experiments. *: P<0.05, **: P<0.01, ***: P<0.001, experimental vs. control. [Diagram 23]Figure 23 shows that Tace is involved in shedding of the short isoform of CD146 in ECFCs. A: ECFCs were transfected with siRNA targeting short (shCD146) or long (IgCD146) isoforms of CD146 and control siRNA, and soluble CD146 (sCD146) secretion was determined in cells treated with TNF 20ng / ml for 24h in basal conditions. Results are the mean + / - SEM of 5 experiments of each type. B: ECFCs treated with TNF 20ng / ml for 24h were transfected with siRNA targeting Tace, ADAM10, MT1-MMP, and control siRNA (C), and soluble CD146 (sCD146) secretion was determined. Results are the mean + / - SEM of 3 experiments of each type. [Figure 24] Figure 24: Characterization of I10-sCD146 and I5-13-sCD146 isoforms. A: Schematic of I10-sCD146 and I5-13-sCD146 isoforms compared to the shed form. Amino acid differences are indicated. B: mRNA expression of I10-sCD146 and I5-13-sCD146 isoforms was analyzed in ECFCs and HUVECs and compared to mRNA expression of short and long isoforms of CD146. Results are the mean + / - SEM of 3 experiments. C: mRNA expression of I10-sCD146 and I5-13-sCD146 isoforms was analyzed in ECFCs by qPCR after cells were treated with shed recombinant soluble CD146 50ng / ml, VEGF 20ng / ml, TNF 20ng / ml, TGFbeta 5ng / ml and Netrin 50ng / ml for 24h. Cells were also treated with WNT5a 20ng / ml for 15min and WNT3a 50ng / ml for 1h. Results are the mean + / - SEM of 3 experiments. *: P<0.05, experimental vs. control. [Diagram 25]Figure 25 shows the effect of I5-13-sCD146 and I10-sCD146 on angiogenesis. A: The effect of siRNA targeting I10-sCD146 and I5-13-sCD146 on ECFC proliferation. Experiments were performed in the presence of GM6001 10μM. Results are the average of 4 experiments of each type, and a representative picture from one experiment is shown. B: The effect of overexpression of I10-sCD146 (p-I10-sCD146) and I5-13-sCD146 (p-I5-13-sCD146) and shed sCD146 (p-shed sCD146) achieved by plasmid transfection on ECFC proliferation. Experiments were performed in the presence of GM6001 10μM. C: Effect of recombinant proteins I10-sCD146, I5-13-sCD146 and shed sCD146 50ng / ml on the proliferation of ECFCs. Experiments were performed in the presence of GM6001 10μM. Results are the average of 4 experiments of each type. D: Yolk sac membrane assays were performed in the presence of I5-13-sCD146 and I10-sCD146 25ng / ml or 50ng / ml and compared to control. Representative pictures of 4 experiments of each type are shown. E: Effect of recombinant protein I10-sCD146, control I5-13-sCD146 and shed sCD146 50ng / ml on the number of sprouts, branching sites and cumulative sprout length in spheroid experiments realized with ECFCs. Results were compared with VEGF 20ng / ml and EGM2-MV complete medium. Mean and representative pictures of experiments are shown. The results are the average of four experiments of each type. *: P<0.05, ***: P<0.001, experimental vs. control. [Figure 26]Figure 26 shows the effect of local injection of recombinant I5-13-sCD146 and I10-sCD146 in a mouse ischemic hindlimb model. A: Ischemic mice were treated with PBS or rh-sCD146 / rh-I10-sCD146 / rh-I5-13-sCD146 or 2 μg VEGF. Blood perfusion rate was monitored by laser Doppler. Results are the average value for each group of six experiments and are expressed as % of the control hindlimb. *,**,***: P<0.05, P<0.01, P<0.001, I10-sCD146 vs. PBS; $$, $$$: P<0.01, P<0.001, I5-l3-sCD146 vs. PBS; ##, ###: P<0.01, P<0.001, shed sCD146 vs. PBS; £: P<0.05, VEGF vs. PBS. B: Vascular examination in hindlimb muscle sections from control (PBS) and shed rh-sCD146 / rh-I10-sCD146 / rh-I5-l3-sCD146 treated animals 28 days after surgery. Blood vessels were visualized by immunofluorescence assay using isolectin B4, **, ***: P<0.01, P<0.001, experimental vs. control. $:P<0.05, I10-sCD146 vs. I5-13-sCD146 labeling. C: Angiograms of control (PBS) and shed sCD146 / I10-sCD146 / I5-13-sCD146 treated animals at D28. Pictures are representative of 6 animals from each group. Mean vascular density was expressed as right vs. left leg in different parts of the limb (sural, thigh) and in the whole leg. *,**:P<0.01,P<0.001, experimental vs. PBS in sural; $:P<0.05, experimental vs. PBS in thigh; #,##:P0.05,P<0.01, experimental vs. PBS in the whole leg. [Figure 27]Figure 27 shows the expression and effect of I5-13-sCD146 and I10-sCD146 isoforms in systemic sclerosis. A: Shedded sCD146, I5-13-sCD146 and I10-sCD146 concentrations were determined in 22 patients with systemic sclerosis compared to matched controls. I5-13-sCD146 was also compared in SSc patients with pulmonary fibrosis and SSc patients without pulmonary fibrosis (inset, n=10 and n=12, respectively). B: Basal Wnt signal activation (b-catenin / TCF transcriptional activity, luciferase assay) was estimated in mouse embryonic fibroblasts (MEFs) from CD146KO and WT mice. MEFs were treated with or without bleomycin in the presence or absence of shed sCD146. Results are the mean + / - SEM of 5 independent experiments. C: Skin thickness was evaluated in a CD146KO mouse model in which systemic sclerosis was induced by subcutaneous injection of bleomycin. The effects of shed sCD146, I5-13-sCD146 and I10-sCD146 were estimated and average values of 4-5 animals of each species are shown. Representative photographs are also shown. D: Skin planes are shown in CD146KO mice of each species, treated with bleomycin, with or without shed sCD146, injected with or without I10-sCD146 and I5-13-sCD146. E: Vascular examination of the skin of animals treated with or without shed sCD146 / I10-sCD146 / I5-13-sCD146. Blood vessels are labeled with isolectin B4. Results are representative of 3 experiments of each species in 4-5 animals. *: P<0.05, **: P<0.01, ***: P<0.001, experimental vs. control. [Figure 28] Figure 28 shows the expression of I5-13-sCD146 and I10-sCD146 isoforms in normal tissues. I10-sCD146 and I5-13-sCD146 mRNA expression was examined in various organs by tissue arrays. Results were normalized as a function of expression in lymph nodes. [Figure 29]Figure 29 shows the effect of UUO (unilateral ureteral ligation) on the expression of CD146 and secretory soluble CD146. A: CD146 expression was observed in kidney sections and quantified in kidneys with UUO and contralateral kidneys. Quantification is shown. B: Soluble CD146 was quantified in sham-operated UUO animals by ELISA. Results are the average of 7 animals. *: P<0.05, **: P<0.01, UUO vs. contralateral. [Diagram 30] Figure 30 shows the effect of antibody treatment on collagen and fibronectin expression. The effect of UUO was observed on protein expression of collagen I, collagen III and fibronectin. The effect of treatment with antibodies was also observed compared to treatment with control IgG. Results are the average of 7 animals in each group. ****: P<0.001, vehicle vs. contralateral §§§§: P<0.001, mAb vs. vehicle ***: P<0.01 vehicle or control IgG vs. contralateral §§§: P<0.01 mAb vs. vehicle [Diagram 31] Figure 31 shows the effect of antibody treatment on a-SMA expression. The effect of UUO on a-SMA expression was observed by immunohistochemistry. The effect of treatment with antibody was also observed compared to treatment with control IgG. Results are the average of 7 animals in each group. ***: P<0.001, vehicle vs. contralateral §§§: P<0.01 mAb vs. vehicle [Diagram 32] Figure 32 shows the effect of anti-sCD146 mAb on a-SMA expression and vimentin mRNA expression in primary cultures of human kidney fibroblasts. The effect of sCD146 (50ng / ml) was examined in primary cultures from human fibroblasts. Effect of anti-sCD146 mAb 500ng / ml, administered alone (Ac) or together with sCD146. Results are the mean + / - SE of three experiments and are expressed as fold change vs. no treatment control condition. *: P<0.05, sCD146 vs. control $: P<0.05, sCD146+Ac vs. sCD146 [Diagram 33]Figure 33 shows the effect of the adenine diet on kidney characteristics. A: Animals were treated with (Adenine) or without (Control) adenine and sacrificed 2 weeks after the end of the adenine diet. Fibrosis was detected after Sirius red staining of kidneys. Representative pictures are shown. B: mRNA expression of TGFb, collagen al and alpha SMA was analyzed in control kidneys and kidneys immediately after the adenine diet (End), 1 week after the end of the adenine diet (week1), 2 weeks after the end of the adenine diet (week2) and 3 weeks after the end of the adenine diet (week3). Results are expressed as variation from the control group. C: Alpha SMA protein expression was analyzed in control kidneys, kidneys immediately after the adenine diet (End), 1 week after the end of the adenine diet (week1), 2 weeks after the end of the adenine diet (week2), and 3 weeks after the end of the adenine diet (week3). Results are presented relative to the control group. D: CD146 mRNA expression was analyzed in control kidneys, kidneys immediately after the adenine diet (End), 1 week after the end of the adenine diet (week1), 2 weeks after the end of the adenine diet (week2), and 3 weeks after the end of the adenine diet (week3). Results are presented as variation from the control group. [Diagram 34] Figure 34 shows the effect of anti-sCD146 antibody on kidney fibrosis in mice treated with adenine. A: Adenine-treated animals were injected with PBS, control IgG or anti-sCD146 mAb. Fibrosis was detected in kidneys after Sirius red staining 2 weeks after the end of the diet. Representative pictures are shown. B: Quantification of fibrotic area is expressed as % of fibrotic area on all surfaces. Results are expressed as + / - SE mean of at least 5 sections from 4 animals in each group. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0029] CD146 is a glycoprotein that belongs to the immunoglobulin superfamily. It is known to be involved in permeability, inflammation and angiogenesis.
[0030] Membrane CD146 is expressed on all endothelial cells of the vascular tree, regardless of vascular caliber or anatomical region. It is an adhesive protein detected in the ges F 1991). It is mainly localized to intercellular junctions and acts as a cellular endothelial cell adhesion and cell Not only the interfacial permeability (Anfosso, F., 2001, Solovey, AN, 2 001, Jouve, N., 2015), monocyte extravasation (Bardin, N., 200 9) and angiogenesis (Chan, B., 2005; Harhouri, K., 2010; Y an,X.,2003, Halt J KI,2016). CD146 also regulates each Species isoforms with putative PDZ-binding motifs that may mediate anchoring to the cytoskeleton There are short isoforms that are thought to be ,E.,1995, Vainio,O.,1996), endocytic motif and and long isoforms with what has been defined as Metalloprotease-mediated shedding of membrane-associated CD146 results in a soluble form (sCD146) (Bardin, N., 2003, Boneberg, EM, 20 sCD146 is detectable in human serum at levels Inflammatory bowel disease (Bardin, N., 2006), abnormal pregnancy (Pasquier, E., 2005) or chronic renal failure (Bardin, N., 2003). It will be shortened.
[0031] The present inventors herein for the first time identified the short membrane isoform and the long membrane isoform of CD146. The new membrane isoform is shed by TNFα-converting enzyme and ADAM10 proteinase. Moreover, RNA sequencing experiments have demonstrated that two alternative sCD1 46 revealed the presence of a splice variant, “I5-13-s "CD146" (or I5-13 soluble CD146) and "I10-sCD146" (or I10 was identified as soluble CD146.
[0032] Moreover, the present inventors have demonstrated that CD146, typically sCD146, can be used as a biomarker. and can be advantageously used in the diagnosis of fibrosis or as a therapeutic tool in the treatment of fibrosis. The above-mentioned features have been discovered and are described herein for the first time.
[0033] CD146 is particularly useful in preventing fibrosis, particularly cardiac, renal, skin and / or pulmonary fibrosis, in a subject. The present invention is advantageous for use in detecting predisposition to, diagnosing and / or predicting or monitoring the prognosis of, a disease.
[0034] In the context of the present invention, as further described herein below, CD146 is typically Typically, CD146 protein, such as membrane-type CD146 or soluble CD146 (sC D146), preferably SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, sCD146 protein selected from sequence number 5, SEQ ID NO: 6 and SEQ ID NO: 7, SEQ ID NO: 8, I5-13 soluble CD146 protein or I10 soluble CD146 protein of SEQ ID NO: 9 The CD146 protein is selected from the group consisting of CD146 and CD146 proteins.
[0035] More precisely, the inventors have now for the first time discovered a soluble form of CD146, in particular the sequence SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7 The sCD146 protein, which is expressed in the inflammatory bowel disease, is involved in causing cardiac and renal fibrosis. Therefore, sC is a biomarker for cardiac and renal fibrosis. D146 stimulates the cells responsible for fibrosis, namely fibroblasts and endothelial cells. Our experiments showed that, in particular, two models of severe renal fibrosis induction (glomerular base pairing) In the basal membrane serum-induced model and the unilateral ureteral obstruction model, CD146 The level of sCD146 was significantly increased in the circulating blood, and its effect on fibrosis was , demonstrating that this is greatly reduced when KO mice for CD146 are used. The present inventors also found that CD146 and sCD146 were increased in a mouse myocardial infarction model, The amount of fibrosis for CD146 in KO animals is reduced compared to control animals after myocardial infarction At the same time, in aged mice, KO CD146 mice compared with wild-type (WT) mice demonstrated that the development of cardiac fibrosis was reduced in
[0036] The present inventors have also discovered soluble forms of CD146, in particular those represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, sCD146 protein selected from SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7 The protein has profibrotic activity in the heart and lungs and thus promotes cardiac and / or renal fibrosis. The phenomenon of fibrosis is therefore a promising therapeutic target for treating fibrosis. , SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO: Inhibitors of soluble CD146 protein selected from the group consisting of sCD1 It can be prevented or reversed in the presence of monoclonal antibodies directed against 46 proteins. do.
[0037] On the other hand, the present inventors have discovered that soluble CD146, in particular, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. A sCD146 tag selected from SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7. The protein has anti-fibrotic activity in the skin and lungs, and thus reduces the incidence of cutaneous fibrosis in subjects. It has been demonstrated that the compounds can be used for the prevention or treatment of pulmonary fibrosis and / or pulmonary fibrosis.
[0038] The present inventors have identified a newly identified isoform I5-13 soluble CD1 of SEQ ID NO:8. Both the CD146 protein and the I10 soluble CD146 protein of SEQ ID NO:9 were found to be associated with fibrosis. It has also been demonstrated that fibrosis is a biomarker for dermal fibrosis and / or pulmonary fibrosis. However, these two isoforms do not vary in the same way. I5-13 soluble CD146 is upregulated in fibrosis, whereas I10 soluble CD146 I5-13 is effective in treating fibrosis, particularly dermal fibrosis and / or pulmonary fibrosis. I10 is a therapeutic target for treating fibrosis, particularly skin fibrosis and / or pulmonary fibrosis. It can be used as a therapeutic tool for the prevention or treatment of fibrosis.
[0039] As indicated herein above, fibrosis occurs following an ischemic event such as myocardial infarction. It can occur in association with immune disorders and during the aging process.
[0040] The term "subject" refers to any testable subject, typically a patient. Preferably, the subject is a mammal, and more preferably a human. The test can be used for both the entire group and the entire community. Anyone can take the test regardless of age or gender.
[0041] "Human long CD146 protein" or "long CD146" refers primarily to is present in the membrane of epithelial cells and has an amino acid sequence corresponding to SEQ ID NO: 10 described herein It refers to a human protein, peptide or amino acid molecule.
[0042] "Human short CD146 protein" or "short CD146" is primarily It is present in the membrane of endothelial cells and has an amino acid sequence corresponding to SEQ ID NO: 11 described herein. The term refers to a human protein, peptide or amino acid molecule.
[0043] "Human soluble CD146 protein" or "soluble CD146" or "sCD146" Typically, sCD refers to a human protein, peptide or amino acid molecule. The l46 protein is typically present in human serum. The CD146 protein is represented by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9 Contains or is contained within.
[0044] SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO: In the context of the present invention, the subject is an animal, in particular a human, among the sequences of SEQ ID NO: 7. A preferred soluble human CD146 protein can be used in any of the above applications.
[0045] The exemplary sCD146 protein according to the present invention, as already explained, has diagnostic relevance. as biomarkers in the field and as therapeutic targets, and as therapeutic or preventive / prophylactic These are proteins that can be used as therapeutic tools in the context of treatment.
[0046] The disclosure further includes nucleic acid sequences encoding each of the proteins of the invention described herein. Describes the child.
[0047] Such nucleic acid molecules typically comprise a biologically active human CD146 protein, in particular a human CD146 polypeptide. RNA or DNA encoding a soluble CD146 protein, or a recombinant thereof. This can be used to prepare a survey form.
[0048] The term "treatment" or "therapy" refers to a line of Fibrosis, typically leading to, resulting from, or associated with any fibrotic human disease Alleviate, mitigate or cure any condition, disease, disorder or impairment that is caused by The term "prophylactic" refers to both therapeutic and prophylactic or preventative treatments or methods that can be used to (reverse) a disease or condition. Examples of such diseases include atrial fibrosis, endomyocardial fibrosis, and infarction, particularly old myocardial infarction. vascular embolism, renal fibrosis, cirrhosis, biliary atresia, progressive massive fibrosis, glial scarring, arteriosclerosis, joint line Fibrosis, Crohn's disease, Dupuytren's contracture, nephrogenic systemic fibrosis, mediastinal fibrosis, retroperitoneal fibrosis These include myelofibrosis, myelofibrosis, and systemic sclerosis.
[0049] Such "treatment" typically refers to a condition already described herein where a need for such treatment has been identified. The subject is typically an animal subject, preferably a human subject. The pathologies that may lead to, result from, or are associated with fibrosis are considered a subject suffering from a condition, disease, disorder or impairment, or a subject suffering from such a pathology, disease, disorder or impairment Subjects who are considered to be at risk of developing a harmful condition, i.e. In subjects in which it is suspected that such a thing will occur, and in such subjects such a thing will be prevented It should be.
[0050] For example, the patient may be diagnosed with fibrosis or a condition that leads to, results from, or is associated with fibrosis. A subject that exhibits one of the pathologies, diseases, disorders, or impairment states described herein. The subject may be, for example, a subject who has a predisposition to (or is suspected of having) cardiac fibrosis. suffer from or have a myocardial infarction (e.g., atrial fibrosis, endomyocardial fibrosis or infarction) or renal fibrosis are subjects who are considered to be "at risk of developing the disease."
[0051] The subject may be asymptomatic or may be at an early stage of the onset of such a condition, disease, disorder or impairment. The symptoms may include early or advanced stages of the disease.
[0052] Typical subjects are those predisposed to fibrosis, affected by fibrosis, or those with non-advanced fibrosis. The present invention relates to a method for treating fibrosis, a method for treating fibrosis, and a method for treating fibrosis. A target identified in the shadows.
[0053] Another particular object of the present invention is to provide a method for the treatment of a pulmonary edema in a subject, typically an animal, preferably a human. , detecting a predisposition to fibrosis, in particular cardiac and / or renal fibrosis, Diagnosis and / or prognosis (to make a diagnosis and / or predict a prognosis) or monitoring of (monitoring) typically for use as a biomarker. No. 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7 The soluble CD146 protein is selected from the group consisting of:
[0054] A preferred human soluble CD146 protein is contained in or is set forth in SEQ ID NO:7.
[0055] A more specific object of the present invention is to provide a method for the preparation of a soluble CD146 protein of I5-13 of SEQ ID NO: 8. detecting a predisposition to fibrosis, in particular dermal fibrosis and / or pulmonary fibrosis, in a subject; Use as a biomarker in the diagnosis and / or prognosis or monitoring of the disease. And so.
[0056] Another particular object of the present invention is to provide a soluble form of CD146 protein, I10, of SEQ ID NO: 9. detecting a predisposition to fibrosis, in particular dermal fibrosis and / or pulmonary fibrosis, in a subject; Use as a biomarker in the diagnosis and / or prognosis or monitoring of the disease. And so.
[0057] In a subject, typically an animal, preferably a human, fibrosis, particularly in the heart, kidney, skin and and / or detection or diagnosis of a predisposition to pulmonary fibrosis and / or prognosis in vitro, Ex vivo or in vivo methods are specifically described herein. In a preferred embodiment relating to fibrosis, the CD146 used in such methods is , SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO: Number 7 is selected.
[0058] In another preferred embodiment relating to skin and / or lung fibrosis, I5-1 of SEQ ID NO: 8 3. The sCD146 used in the soluble CD146 protein is represented by the sequence I10 of SEQ ID NO: This is the soluble form of CD146 protein.
[0059] The term "diagnosis" or "diagnosing" refers to the determination of a condition, as defined herein, in a subject. , detection or identification of a disease, disorder or dysfunction condition, typically fibrosis, or It refers to the evaluation (quantification and comparison) of the state of a pathological condition, disease, disorder, or functional impairment such as vinegar.
[0060] In a particular embodiment, the diagnostic method of the invention involves detecting CD146, typically sCD146 protein. Determining the presence of protein and / or CD146 present in a biological sample of the subject, typically It involves measuring the amount of sCD146 protein and, preferably, comparing the amount to a reference value.
[0061] The term "prediction" or "predicting" refers to a process in which the object is to predict Refers to the assessment of a predisposition to develop a condition, disease, disorder or impairment as defined in the subdivision. vinegar.
[0062] The term "diagnosis" or "diagnosing" refers to the diagnosis of a condition, disease, disorder or To assess or monitor the progress of a subject with or without treatment for a condition that impairs function. - predicting adverse effects typically associated with the worsening of such a disease or disorder, or , conversely, refers to the prediction of improvement in a subject's health.
[0063] The diagnostic method of the present invention involves detecting early, pre-diagnostic factors such as CD146, typically the CD146 protein. The amounts or levels measured at various stages, including the prodromal and post-symptomatic stages, were analyzed using one or more The method includes one or more steps of monitoring, quantifying, and comparing in multiple biological samples. It may include.
[0064] Prognosis is typically determined by assessment of fibrosis progression ( The predictions and features of interest.
[0065] The methods described herein typically involve detecting, in a biological sample from a subject, the expression of CD146, in particular and verifying the presence of sCD146, i.e., the expression of CD146 protein. and preferably determining the level of CD146 expression (measurement of the amount of CD146) and determining.
[0066] In particular, any of the human CD146 proteins described herein, typically human soluble The CD146 protein is administered to a subject, typically an animal, preferably a human, to treat fibrosis or other conditions. may indicate the presence of a fibrosis-related disease, in particular cardiac, renal, skin and / or pulmonary fibrosis. It can be used as a biomarker.
[0067] In certain embodiments, the method of diagnosing and / or prognosing fibrosis in a subject comprises administering to a subject a soluble determining in the subject's biological sample the level of CD146 protein expression. The soluble CD146 protein is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: step i) selecting from number 4, SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7; and ii) comparing the expression level determined in i) with a reference value, e.g. a predefined reference value; and if the level determined in step i) is higher than the reference value, the subject is diagnosed with fibrosis. conclude that the patient is predisposed to, affected by fibrosis, or has a poor prognosis; or If the level determined in step i) is lower than the reference value, the patient is predisposed to fibrosis. The conclusion is that the patient does not have fibrosis, is not affected by fibrosis, or has a good prognosis. Step iii).
[0068] In another particular embodiment, the present invention relates to a method for detecting or diagnosing a predisposition to fibrosis in a subject. The method for predicting and / or predicting prognosis includes administering soluble I5-13 CD146 protein of SEQ ID NO: 8 to a patient. The expression levels of the soluble CD146 protein of I10 of SEQ ID NO: 9 were measured in the biological samples of the subjects. The method includes determining in a rule.
[0069] More precisely, in one embodiment, the method comprises the steps of: determining an expression level in a biological sample of the subject; step ii) of comparing the expression level determined in step i) with a reference value; If the detected level is higher than the reference level, the subject is deemed to be predisposed to fibrosis, or is affected by fibrosis. or conclude that the patient has a poor prognosis or that the level determined in step i) is below the baseline. A value lower than the threshold indicates that the patient is not predisposed to fibrosis and is not affected by fibrosis. or iii) concluding that the patient has a favorable prognosis.
[0070] In another embodiment, the method comprises measuring the expression level of I10 soluble CD146 protein in a subject. and determining in a biological sample the expression of a step ii) of comparing the level with a reference value; and A lower reference value indicates that the subject is predisposed to, affected by, or has a predisposition to fibrosis. conclude that the patient has a poor prognosis or that the level determined in step i) is higher than the reference value is higher, the subject is not predisposed to, not affected by, or is not at risk for fibrosis. and iii) concluding that the patient has a good prognosis.
[0071] The terms "reference value", "control value" and "cut-off value" refer to the value of a reference population, typically a healthy individual. A living subject is a healthy subject, i.e., a subject not in a state of pathology, disease, disorder or impairment. The basal value (Basa) corresponds to the average of the values (measurement level, amount or concentration) obtained using the It may also refer to the I / O Value.
[0072] Reference values are also used to describe statistical or discriminatory values, i.e., values that are useful for comparing healthy control populations with those with known pathologies, diseases, or conditions. and measuring parameters in both the population with the disorder or impairment condition. The discriminatory value may be a value determined by comparing the parameter value with the healthy control population and the patient population. A predetermined specificity and / or a predetermined sensitivity based on an analysis of the relationship between the known clinical data and The discriminatory value thus determined will be useful in future individual testing. For example, the reference value is I5-13 soluble CD14 6 protein at 300ng / ml, I10 soluble CD146 protein at 300ng / ml can be 50 ng / ml.
[0073] Certain methods described herein include treating fibrosis, particularly cardiac or renal fibrosis, in a subject by: This method is a method for monitoring in vitro, ex vivo or in vivo. In a biological sample from a subject, the expression level of soluble CD146 protein or determining the presence and amount of soluble CD146 protein, Soluble CD146 proteins are represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7, and a biological sample of a subject at an early time point in subject biological samples at later time points compared to baseline values obtained in the pool. The presence (following absence) or increased expression level of CD146 protein in a subject The results showed increased fibrosis or worsening of fibrosis, while the levels of soluble CD146 protein were decreased. showed reduced fibrosis and equal soluble CD146 protein levels in subjects This indicates that fibrosis is stable or, in other words, is not progressing.
[0074] Another particular method described herein involves administering to a subject in vitro, in vivo or ex vivo A method for monitoring fibrosis in a subject, the method comprising administering to the subject an I5-13 soluble C of SEQ ID NO: 8. Determining the expression level of D146 protein in a biological sample from the subject at least twice. and expression of soluble CD146 protein in a biological sample of the subject at a later time point. The level is higher than a baseline value obtained at an earlier time point in a biological sample of the subject. showed increased fibrosis in subjects, whereas human soluble CD146 protein The lower levels of human soluble CD146 protein indicate a reduction in fibrosis. The positive result indicates that fibrosis is not progressing in the subject.
[0075] Another particular method described herein involves administering to a subject in vitro, in vivo or ex vivo A method for monitoring fibrosis in a subject, the method comprising administering to the subject an I10 soluble CD1 determining the expression level of 46 proteins in a biological sample from the subject at least twice , expression levels of soluble CD146 protein at later time points in biological samples of subjects is lower compared to baseline values obtained at earlier time points in subject biological samples. showed increased fibrosis in elephants, while human soluble CD146 protein levels were Higher levels indicate reduced fibrosis, and equal levels of human soluble CD146 protein indicates that fibrosis is not progressing in the subject.
[0076] To assess the progression of fibrosis or to regulate the efficacy of treatment, Patients are tested before any treatment and the same patients are tested under treatment (typically without any pre-existing conditions). It may be useful to test after a few days, weeks or months (in this condition). In that situation, the results (measurements) of the second test were compared to the results of the first test.
[0077] "Above the reference value" or "higher than the reference value" refers to CD146 expression / level, for example: It may mean a statistically significant increase of at least two standard deviations.
[0078] The term "biological sample" refers to any sample from a subject, particularly an animal subject, typically a human. Biological samples include tissue biopsies, e.g., cardiac biopsies, or biological fluid samples. It may be a body sample.
[0079] Typical examples of biological samples that can be used in the context of the present invention are plasma, blood, serum, The biological sample may be selected from a urine, cerebrospinal fluid and saliva sample. Preferably, the biological sample is a blood sample. The sample is preferably a plasma, blood, or serum sample, and even more preferably a serum sample. The sample is preferably a diluted sample, the dilution being typically 1 / 25, ... 1 / 50, 1 / 100, 1 / 200 or 1 / 400, preferably 1 / 25.
[0080] In particular, serum concentrations of the possible CD146 protein may be useful in the detection, diagnosis, and treatment of fibrosis predisposition. Elevated values may be indicated in prognostic or monitoring methods. Indeed, measurements may be used to assess the health of a subject. It can be compared to standard values associated with the state. In particular, CD146, typically SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5. sCD146 selected from SEQ ID NO: 6 and SEQ ID NO: 7 or I5-13 of SEQ ID NO: 9 Overexpression of soluble CD146 protein may indicate the presence of fibrosis.
[0081] Preferably, the determination of the presence and measurement of the amount of CD146, in particular sCD146, is performed in the context of a subject's biological activity. The body sample is directly contacted with a suitable anti-CD146 antibody or by a one-step method. The antibody titer is determined in an immunoassay by a method involving pretreatment of the antibody.
[0082] Binds to CD146, particularly sCD146, and identifies it in a biological sample of a subject. Antibodies capable of detecting / quantitating the antibody are known in the art. Preferred antibodies include Monoclonal antibodies, preferably CD146, in particular sCD (for membrane-type CD146) It is a monoclonal antibody that selectively binds to 146.
[0083] A particular antibody that selectively binds to sCD146 has the sequence ID No. 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO: Proteins comprising or in the sequence of SEQ ID NO: 8 and SEQ ID NO: 9, preferably SEQ ID NO: 7 , selectively binds to proteins comprising or in the sequence SEQ ID NO:8 and SEQ ID NO:9 The antibody may be selected from the group consisting of:
[0084] Advantageously, the antibody of the present invention selectively binds to sCD146 (relative to membrane-type CD146). The antibody comprises the heavy chain variable region (VH) CDR fragments of SEQ ID NO:87, SEQ ID NO:88 and SEQ ID NO:89. The peptide sequences and the light chain variable region (VL) of SEQ ID NO: 90, sequence QVS and SEQ ID NO: 91 and CDR polypeptide sequences. SEQ ID NO:87 corresponds to the following amino acid sequence: GYTFTSHF. SEQ ID NO:88 corresponds to the following amino acid sequence: IFPGSGDT. SEQ ID NO:89 corresponds to the following amino acid sequence: ARTWAY. SEQ ID NO:90 corresponds to the following amino acid sequence: QSLLYSDGKTY. SEQ ID NO:91 corresponds to the following amino acid sequence: AQTTHFPLT.
[0085] In a particular embodiment, the antibody or fragment thereof according to the invention comprises SEQ ID NO: 93 It comprises a light chain variable region (VL) and a heavy chain variable region (VH) comprising SEQ ID NO:92.
[0086] Advantageously, the antibody of the present invention selectively binds to sCD146 (relative to membrane-type CD146). The antibody comprises the heavy chain variable region (VH) CDR fragments of SEQ ID NO:94, SEQ ID NO:95 and SEQ ID NO:96. The peptide sequence and the light chain variable region (VL) of SEQ ID NO: 97, sequence FAS and SEQ ID NO: 98 and CDR polypeptide sequences. SEQ ID NO:94 corresponds to the following amino acid sequence: GFTFSDYG. SEQ ID NO:95 corresponds to the following amino acid sequence: IYYDSSKM. SEQ ID NO:96 corresponds to the following amino acid sequence: AAFQFDY. SEQ ID NO:97 corresponds to the following amino acid sequence: QGISTS. SEQ ID NO:98 corresponds to the following amino acid sequence: QQSYNLPYT.
[0087] In a particular embodiment, the antibody or fragment thereof according to the invention comprises SEQ ID NO: 100. and a heavy chain variable region (VH) comprising SEQ ID NO:99.
[0088] Any of the antibodies described herein can be incorporated into a composition, typically a diagnostic composition. and pharma- ceutically acceptable carriers or carriers can be readily determined by one of skill in the art. Further included are each in appropriate dosages as described above.
[0089] The antibody that binds to CD146 is typically used or present in the composition in an effective amount. An "effective amount" of expression is defined as the amount of CD146, particularly sCD146, administered to a subject or to a biological sample of a subject. The term "anti-CD146 antibody" refers to an amount or concentration of anti-CD146 antibody sufficient to be detected and / or measured in a sample.
[0090] Exemplary anti-CD146 antibodies for use in diagnostic contexts in animals, typically humans. The effective amount is between about 1 μg / ml and 5 μg / ml, preferably between about 1 μg / ml and about 2.5 μg / ml, or between about 2.5 μg / ml and about 5 μg / ml.
[0091] Immunoassays are carried out in a solid or homogeneous phase by methods well known in the art. This can be done in one or two steps, for example by competitive methods. More preferably, the immunoassay is an ELISA, a FEIA, a Western blot, Choose from dot blots, bead-based assays, antigen arrays and radioimmunoassays can be.
[0092] In an ELISA, an antigen is immobilized on a solid surface and complexed with an antibody linked to an enzyme. Detection is achieved by reacting with a substrate to produce a colored product. This is accomplished by incubation and then assessing the activity of the bound enzyme.
[0093] In FEIA, the colored product is fluorescent.
[0094] In a radioimmunoassay, the end product is radioactive.
[0095] Detection of proteins using the dot blot protocol is compatible with both Western blot and The method is similar in that it allows the identification and analysis of the protein. The Western blot technique differs from the traditional Western blot technique in that it uses electrophoresis on protein samples. It differs by not using separation. Instead, the sample proteins are bound to the membrane. The beads are dotted on the surface and hybridized with an antibody probe. Ray will enable researchers to simultaneously perform multiple analytes in biological and environmental samples. It's a new approach to measurement.
[0096] Semi-quantitative measurements may be performed using normal controls, for example to normalize values and obtain ratios. or using a positive control as a calibrator (expressed in arbitrary units) Each of the methods described above can be used to obtain the above-mentioned.
[0097] Detection can be achieved by detecting and binding CD146 in one or various forms to a solid support, e.g. A method for arranging multiple antibodies in an orderly manner to measure and / or quantify the It can be carried out in microplaques, solid particles, test tubes, etc. stomach.
[0098] The antibody may be an antibody that binds soluble CD146 protein, e.g., an antibody that binds membrane-type CD146. and) an antibody that selectively binds a soluble CD146 protein, in particular, an antibody having SEQ ID NO: 7. In certain embodiments, the test subject is a soluble CD146 protein comprising or consisting of The level of soluble CD146 protein in the serum of , indicative of fibrosis or increased fibrosis, in particular increased cardiac and / or renal fibrosis or fibrosis.
[0099] The antibody binds to a soluble CD146 protein comprising or consisting of SEQ ID NO:8. In another particular embodiment, the antibody binds to the The level of said I5-13 soluble CD146 protein in serum is increased compared to the baseline level. An increase in the level of fibrosis or increased fibrosis, particularly dermal fibrosis and / or pulmonary fibrosis, or They show increased fibrosis.
[0100] The antibody binds I10 soluble CD146 protein comprising or consisting of SEQ ID NO:9. In another particular embodiment, the antibody is an antibody that inhibits The level of said I10 soluble CD146 protein is elevated compared to baseline levels. shows a reduction in fibrosis, in particular a reduction in dermal fibrosis and / or pulmonary fibrosis.
[0101] The inventors also provide a method for diagnosing fibrosis, in particular cardiac or renal fibrosis, in a subject. The method typically involves detecting levels of CD146, preferably CD147, in the serum of a subject. or detecting, preferably measuring / quantifying, the amount of sCD146. The method typically includes administering to the subject a CD146 protein, preferably a CD146 antibody, as described herein. An antibody that binds the sCD146 protein must be used.
[0102] The inventors also provide herein a method for producing a subject, typically a line, by the methods described herein. Having a predisposition to fibrosis, being affected by fibrosis, having incomplete fibrosis, or having increased fibrosis The present invention relates to a method for treating fibrosis, particularly cardiac fibrosis, in subjects who have been identified as having advanced fibrosis or a poor prognosis for fibrosis. Prevention or treatment of hepatic and / or renal fibrosis, any pathology, disease, disorder or dysfunctional state CD146 inhibitors for use in the treatment of cancer, in particular SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, Soluble CD146 proteins selected from sequence number 4, sequence number 5, sequence number 6 and sequence number 7 Inhibitors of the protein or compositions comprising such CD146 inhibitors are described.
[0103] The inventors also provide herein a method for producing a subject, typically a line, by the methods described herein. Having a predisposition to fibrosis, being affected by fibrosis, having incomplete fibrosis, or having increased fibrosis In subjects who have been identified as having advanced fibrosis or a poor prognosis for fibrosis, Dermal fibrosis and / or pulmonary fibrosis, in particular pulmonary fibrosis associated with systemic sclerosis, Any condition, disease or disorder that leads to, results from, or is associated with fibrosis. or I5-13 of SEQ ID NO: 8 for use in the prevention or treatment of a dysfunctional condition Soluble CD146 protein inhibitors and compositions containing such CD146 inhibitors are described. do.
[0104] fibrosis, resulting from fibrosis, or associated with fibrosis, Overexpression of a form of CD146, typically sCD146, or the CD146 receptor The pathology, disease, disorder or impairment state described herein is characterized as being present: Advantageously, the CD146 inhibitor preferably inhibits CD146, preferably human CD14 6, or any other such CD146-directed antibody. D146 antagonists, and as described herein, the inventors have demonstrated In this regard, such CD146 inhibitors, once administered to a subject, prevent and halt fibrosis. They discovered that it was possible to stop the vehicle and even reverse it.
[0105] In particular, the present description relates to methods for preparing compositions, typically pharmaceutical compositions, in vitro or ex vivo. fibrosis, in particular cardiac, renal, skin and / or pulmonary fibrosis or fibrosis leading to Any condition, disease, disorder or mechanism resulting from or associated with fibrosis. US20100223633A1 - CD146 inhibitors for preventing or treating a condition of impaired function in a subject in need thereof - Google Patents , preferably SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, soluble CD146 protein inhibitor selected from SEQ ID NO: 6 and SEQ ID NO: 7, 5-13 Soluble CD146 protein inhibitor or composition containing such CD146 inhibitor Concerning the use of things.
[0106] In an exemplary embodiment, the CD146 inhibitor is an antibody, an aptamer, a polypeptide, an organic The molecule is selected from a small molecule and a nucleic acid.
[0107] In a preferred embodiment, the CD146 inhibitor is an anti-CD146 antibody or an anti-CD146 antibody. an original binding molecule, preferably an anti-sCD146 antibody or an sCD146 antigen-binding molecule, Functional fragments (i.e., fragments capable of binding to CD146) or derivatives thereof It is.
[0108] The term "antibody" is used in its broadest sense and refers to any antibody that is capable of inhibiting a desired (e.g., fibrosis) As long as it shows biological activity, monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, etc. Ranging from reclonal antibodies, polyspecific antibodies, chimeric antibodies, humanized antibodies and antibody fragments. An antibody fragment contains a portion of a full-length antibody, generally the antigen-binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab')2 and Fv fragments. , diabodies, linear antibodies, single chain antibody molecules, (e.g. camelid) single domain antibodies, There are NAR single domain antibodies, and multispecific antibodies formed from antibody fragments. The antibody fragments also include VH regions (VH, VH-VH), anticalins (anticalins), and the like. in: Registered trademark), PepBodies, Antibody T cell epitope fusions ( Troybodies or Peptibodies, but not limited to It may refer to a binding moiety comprising a CDR or an antigen-binding domain that comprises them. The body can also detect antibodies against other subtypes, including IgG, IgA, IgD1, IgE1, and Ig Antibodies can be of any class, including human, murine (mouse or rat), of mammalian or avian origin, including donkey, sheep, goat, rabbit, camel, horse or chicken The antibody can be modified by covalently attaching any type of molecule to the antibody. For example, but not limited to, antibody derivatives can be prepared by, for example, glycosylation. , acetylation, pegylation, phosphorylation, amidation, known conservation Derivatization with protecting / blocking groups, protein cleavage, intracellular ligands or other proteins etc., or other modifications known in the art.
[0109] Generally, antibodies (including polyclonal, monoclonal and hybridoma antibodies) Techniques for preparing the antibody and detecting the antigen using the antibody are described in, for example, Harlo w and Lane, Using Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Pr ess, Cold Spring Harbor, NY, 1998; Koh ler and Milstein, Nature 256:495-497 (1975) ; Kozbor et al., Immunology Today 4:72 (1983); and Cole et al., pp. 77-96 in Monoclonal Anti It is well known in "The Human Body and Cancer Therapy, 1985" .
[0110] Moreover, the antibodies of the present invention may be modified to include marker sequences, such as peptide tags, to facilitate purification. A suitable tag is a hexahistidine tag. The antibodies can be used for diagnostic or The therapeutic agent may also be conjugated by methods known in the art. Techniques for preparing such conjugates are well known in the art. Methods for preparing monoclonal antibodies, as well as chimeric, humanized and single chain antibodies, are well known in the art. In certain embodiments, the anti-CD146 antibody is a human soluble CD146 protein. Proteins, preferably comprising or having the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 8. Specifically recognizes / selectively binds to a protein or epitope thereof.
[0111] The antibody preferably comprises the sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, No. 5, SEQ ID NO: 6 and SEQ ID NO: 7 target CD146 protein, in particular target soluble CD1 46 protein and / or I5-13 soluble CD146 protein of SEQ ID NO: 8, preferably or neutralizes the biological activity of the target human soluble CD146 protein. The clonal antibodies reduce or inhibit fibrosis in a subject as defined herein.
[0112] Certain monoclonal antibodies also bind to soluble CD146 receptor or CD146 protein. Reducing or suppressing excess expression (relative to standard expression) of receptor subunits Human CD146 protein, typically human soluble CD146 protein, and C D146 or soluble CD146 protein receptor (or CD146 protein receptor Subunits) may also be used in the context of the present invention. Methods for producing such antibodies are known in the art (e.g., Despo ix N, Walzer T, Jouve N, Blot-Chabaud M, Bardin N, Paul P, Lyonnet L, Vivier E, Dignat-George F, Vely F. Mouse CD146 / MCA M is a marker of natural killer cell mat uration. Eur J Immunol. 2008;38: 2855-64 (see ).
[0113] Soluble CD146 (as opposed to membrane-type CD146) can be used in the context of the present invention. The preferred antibody selected by the inventors is capable of selectively binding SEQ ID NO: 87, sequence 88, the heavy chain variable region (VH) CDR polypeptide sequence of SEQ ID NO: 89 and SEQ ID NO: 9 0, sequence QVS and the light chain variable region (VL) CDR polypeptide sequence of SEQ ID NO: 91. or the heavy chain variable region (VH) CD of SEQ ID NO: 94, SEQ ID NO: 95 and SEQ ID NO: 96. R polypeptide sequence and the light chain variable region (V and L) a CDR polypeptide sequence.
[0114] In certain embodiments, the antibody comprises a light chain variable region (VL) comprising SEQ ID NO: 93 and a light chain variable region (VL) comprising SEQ ID NO: and a heavy chain variable region (VH) comprising:
[0115] In another particular embodiment, the antibody comprises a light chain variable region (VL) comprising SEQ ID NO: 100 and and a heavy chain variable region (VH) comprising sequence number 99.
[0116] The CD146 inhibitor may also be an aptamer. Aptamers are molecules that act like antibodies in terms of molecular recognition. Aptamers are a type of molecule that represents an alternative to the conventional method of binding to a target molecule of any type. Oligonucleotides or oligopeptides with affinity and specificity and the ability to be visually recognized Such ligands are described in Tuerk C. and Gold L., 1990 As described in, the product was isolated by in vitro selection of random sequence libraries (SELEX method). The random sequence library may be generated by combinatorial chemical synthesis of DNA. In this library, each member is a unique sequence, The possible modifications, uses and properties of this type of molecule are described in The benefits and uses of peptide aptamers are reviewed in Jayasena SD, 1999. The mers are selected from combinatorial libraries by a two-hybrid method. Conformational restriction, as demonstrated by platform proteins such as E. coli thioredoxin A, It consists of a restricted antibody variable region.
[0117] In another embodiment, the CD146 inhibitor is a peptide or polypeptide comprising the amino acid residue. It is a do molecule.
[0118] As used herein, the term "amino acid residue" refers to an amino acid residue in either the (L) or (D) configuration. Refers to any natural / standard amino acid residue and non-natural / non-standard amino acid residue, and is These include isoleucine, leucine, lysine, methyl onine, phenylalanine, threonine, tryptophan, valine, arginine, arane Asparagine, Aspartic acid, Cysteine, Glutamic acid, Glutamine, Glycine , histidine, proline, serine, and tyrosine. Propionic acid, 2,3-diaminopropionic acid, α-aminoisobutyric acid, 4-aminobutyric acid, N -Methylglycine (sarcosine), hydroxyproline, ornithine (e.g., L-ol L-ornithine, citrulline, t-butylalanine lalanine, t-butylglycine, N-methyl Leu-isoleucine, phenylglycine, cyclohexylalanine, cyclopentylalanine , cyclobutylalanine, cyclopropylalanine, cyclohexylglycine, cyclopenta butylglycine, cyclopropylglycine, norleucine (Nl e) Norvaline, 2-naphthylalanine, pyridylalanine, 3-benzothienylalanine phenylalanine, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine Niralanine, 4-fluorophenylalanine, penicillamine, 1,2,3,4-tetraphenylalanine Hydro-isoquinoline-3-carboxylic acid, β-2-thienylalanine, methionine sulfonate oxide, L-homoarginine (hArg), N-acetyl-lysine, 2-aminobutyric acid, 2- Aminobutyric acid, 2,4-diaminobutyric acid (D- or L-), p-aminophenylalanine, N -Methylvaline, selenocysteine, homocysteine, homoserine (HoSer), cys Theic acid, ε-aminohexanoic acid, δ-aminovaleric acid, 2,3-diaminobutyric acid (D- or L-aminobutyric acid) -), etc. Such amino acids are well known in the art of biochemistry / peptide chemistry. It is.
[0119] As used in the context of the present invention, a peptide-containing compound is a compound having at least one peptide bond. In addition, isosteric modification of one peptide bond The compounds of the invention, which include peptides, may include substitutions by peptidomimetics. Peptide mimetics typically involve the polarity of the peptide equivalent, It has the characteristic of maintaining three-dimensional size and functionality (biological activity), and one of the peptide bonds at least one of the amino acid residues is replaced by a more stable proteolytic bond. In general, the bond that replaces the amide bond (amide bond surrogate) has the characteristics of the amide bond. Many or all of the following properties are considered: conformation, steric volume, electrostatic properties, hydrogen bonding properties Typical peptide bond replacements include esters, polyamines and their derivatives. conductors, and substituted alkanes and alkenes such as aminomethyl and ketomethylene. For example, peptides may include -CH2NH-, -CH2S-, -CH2-CH2-, -CH=C H-(cis or trans), -CH(OH)CH2- or -COCH2- bonds one or more peptide bonds substituted by -N-NH-, -CHNHNH-, i.e. In some cases, the side chain may be attached to a nitrogen atom instead of a carbon atom, resulting in a peptoid bond. Such peptide mimetics have high chemical stability and biochemical / pharmacological properties (e.g., half-life, absorption, potency, efficiency, etc.) and / or peptide equivalents. The antigenicity to the IgG antibody (IgG equivalent) may be reduced.
[0120] In another embodiment, the CD146 inhibitor is a small organic molecule.
[0121] The term "organ" refers to molecules of similar size to the organic molecules commonly used in pharmaceuticals. The term excludes biological macromolecules (e.g., proteins, nucleic acids, etc.). Preferred small organic molecules are up to about 5000 Da in size, more preferably up to 2000 Da. , most preferably in the range of up to about 1000 Da.
[0122] In another embodiment, the CD146 inhibitor is a nucleic acid.
[0123] The CD146 inhibitor is typically a polynucleotide or an oligonucleotide, typically The inhibitor nucleotides can be short interfering RNA (siRNA). , microRNA (miRNA) and synthetic hairpin RNA (shRNA), antisense Nucleic acid, complementary DNA (cDNA) or guide RNA (associated with CRISPR-Cas9) In some preferred embodiments, the gRNA can be used in 6 expression is targeted by siRNA. Interference with the function and expression of sex genes has been demonstrated in a variety of organisms. Fire et al., “Potent and Specific Genet ic Interference by Double-Stranded RNA i n Caenorhabditis elegans” Nature 391 :80 6-811 (1998); JR Kennerdell& RW Ca rthew,“Use of dsDNA-Mediated Genetic Int erference to Demonstrate that frizzled a nd frizzled 2 Act in the Wingless Pathwa y,” CeJ 95:1017-1026 (1998); F. Wianni & M. Zernicka- Goetz, “Specific lnterferen ce with Gene Function by Double-Stranded RNA in Early Mouse Development,” Nat. C See, e.g., E. Biol. 2:70-75 (2000). siRNAs are self-complementary. The siRNA may comprise a hairpin loop containing a double-stranded sequence. 0 or less base pairs, for example, about 30 bps or less, as known in the art. It can be produced by approaches including the use of complementary DNA strands or synthetic approaches. Such double-stranded RNAs can be synthesized by in vitro transcription of single-stranded RNAs read from both directions of the template, and by PCR. The sense and antisense RNA strands are synthesized by in vitro annealing. The CD146-targeting double-stranded RNA can also be expressed in cDNA vector constructs. In one embodiment, the CD146 gene (e.g., the human CD146 gene) can be synthesized from the After cell transduction, R The DNA is transcribed, followed by reannealing of the complementary strand. The double-stranded RNA is introduced into cells by transfection of the appropriate construct. It can be done.
[0124] Typically, siRNA-, miRNA- or shRNA-mediated RNA interference occurs at the translational level. In other words, the interfering RNA molecule inhibits the transcription of the corresponding mRNA. It prevents the translation of the molecule, leading to its degradation. RNA interference also acts at the transcriptional level, In this way, the interfering RNA molecule may disrupt transcription of the genomic region that corresponds to it.
[0125] The structure and function of such interfering RNA molecules are well known in the art, e.g. RF Gesteland et al., eds, “The RNA W orld” (3rd, Cold Spring Harbor Laborator y Press, Cold Spring Harbor, NY, 2006) , pp. 535-565, which is incorporated herein by reference. For such an approach, cloning and transfer into a vector is used. Cation techniques are also well known in the art and are described, for example, in J. Sambrook & DR Russell, “Molecular Cloning: A Labo ratory Manual” (3rd, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 20 01), which is incorporated herein by reference.
[0126] In addition to double-stranded RNA, other nucleic acid agents targeting CD146 may also be used in the practice of the present invention. For example, antisense nucleic acids can be used. Antisense nucleic acids can be used to target specific genes in cells. A DNA or RNA molecule that is complementary to at least a portion of a specific target mRNA molecule. In the cell, the single-stranded antisense molecule hybridizes to the mRNA and forms a double-stranded fragment. The cell does not translate the mRNA into this double-stranded form. Sense nucleic acids interfere with the translation of mRNA into protein, thus limiting the expression of a gene to its m It is transcribed into RNA. Antisense methods can block the expression of many genes in vitro. For example, C. J. Marcus-Sekura, “Tec hniques for Using Antisense Oligodeoxyri bonucleotides to Study Gene Expression,” Anal. Biochem. 172:289-295 (1988); J.E. Hambor et al., “Use of an Epstein-Ban V irus Episomal Replicon for Anti-Sense RN A-Mediated Gene Inhibition in a Human Cy totoxic T-Cell Clone,” Proc. Natl. Acad. Sci. USA 85:4010-4014 (1988); H Arim a et al., “Specific inhibition of Interle ukin- 10 Production in Murine Macrophage -Like Cells by Phosphorothioate Antisens e Oligonucleotides,” Antisense Nucl. d Drug Dev. 8:319-327 (1998); and W.-F. Hou et al., “Effect of Antisense Oligodeo xynucleotides Directed to Individual Cal modulin Gene Transcripts on the Prolifer ation and differentiation of PC12 Cells, ” Antisense Nucl. Acid Drug Dev. 8:295-3 08 (1998), which is incorporated herein by reference in its entirety. The technology is further described in C. Lichtenstein & W. Nellen, ds.,“Antisense Technology: A Practical A The paper is described in “The and is incorporated herein by reference. The D146 polynucleotide sequence is already available in the art. Inhibitory nucleotides (e.g., siRNA, miRNA or shRNA) targeting 146 A) can be readily synthesized using methods well known in the art.
[0127] Exemplary siRNAs according to the present invention are 29 bps, 25 bps, 22 bps, 21 bps , 20bps, 15bps, 10bps, up to 5bps or any number between such numbers It may have any integer number of base pairs. The companies include DNAengine Inc. (Seattle, Washington) and Ambion, Inc. (Austin, Texas).
[0128] The amino acid molecules of the present invention are useful in determining their potency and / or efficacy in a subject, typically a mammal, preferably a human. The present invention can be designed to improve biocompatibility with diagnostic, therapeutic or prophylactic uses in patients with It can be used, for example, in various types of tissues, particularly pathological tissues, preferably in humans. To target the target tissue, usually the heart or kidney, the polypeptide is glycosylated and methylated to another polypeptide. The amino acid sequence can be substituted, acetylated, phosphorylated or fused.
[0129] The inventors also refer herein to a method for treating a patient suffering from atopic dermatitis, typically comprising administering to the patient a therapeutically effective amount of a CD146 inhibitor, Compositions are provided that include a pharma- ceutically acceptable excipient, carrier, vehicle or carrier.
[0130] The composition may include several different CD146 inhibitors, e.g., CD146-directed antibodies in a particular formulation. Anti-CD146 antibodies of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, A soluble CD146 protein selected from SEQ ID NO: 6 and SEQ ID NO: 7 and SEQ ID NO: 8 I5-13 soluble CD146 protein, as well as the same or different formulations of CD146 The antibody may comprise different anti-CD146 antibodies.
[0131] Any of the antibodies described herein may further be administered in the presence of a pharma- ceutically acceptable carrier or vehicle. and the like, each in an appropriate dosage that can be easily determined by one of skill in the art. It is okay to do so.
[0132] The composition further comprises a different compound that is not a CD146 inhibitor and is intended for the prevention or treatment of fibrosis. The composition may include an additional therapeutic compound.
[0133] In a particular embodiment, antibodies, particularly directed against the human soluble CD146 described herein, are The compositions described herein comprising the antibodies described herein may further comprise at least one other anti-fibrotic agent. In the context of the present invention, the anti-fibrotic factor may further comprise an anti-fibrotic factor that inhibits the expression of fibroblasts. or inhibits or interferes with the deposition of extracellular matrix.
[0134] Anti-fibrotic factors that can be used in the context of the present invention include bone morphogenetic protein 7 (BMP7). , relaxin, glitamin, and miRNA (e.g., mir-29 or miR-101). A "therapeutically effective amount" of a CD146 inhibitor is an amount that is The present invention is capable of preventing or treating fibrosis in a subject, typically a mammal, preferably a human. A typical therapeutically effective amount for use in a mammal, typically a human, is about Between 5 mg / kg and 15 mg / kg, for example, between about 5 mg / kg and 10 mg / kg or about 1 Between 0 and 15 mg / kg.
[0135] Pharmaceutically acceptable additives, carriers, vehicles or The carrier may be, for example, saline, optionally a stable solution such as isogenic albumin. Manniferum combined with a stabilizing agent or any other stabilizing protein, glycerol, etc. An isotonic buffer such as 20% tetroxide and an azidopropyl ether such as polybrene or DEAE dextran. It is Hubant.
[0136] The composition typically is for preventing or treating fibrosis, in particular cardiac and / or renal fibrosis, in a subject. is for therapeutic use.
[0137] As described herein, including the I5-13 soluble CD146 protein inhibitor of SEQ ID NO:8. Certain compositions and pharma- ceutical acceptable carriers are useful for treating pulmonary fibrosis, particularly systemic fibrosis, in a subject. The present invention is intended for the prevention or treatment of pulmonary fibrosis associated with chronic sclerosis.
[0138] Particular compositions described herein include SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 , SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7; or The present invention relates to a method for the preparation of a soluble CD146 protein having the I10 sequence of SEQ ID NO: 9 and ... soluble CD146 protein having the I10 sequence of SEQ ID NO: 9. Prevention of skin fibrosis and / or pulmonary fibrosis, in particular pulmonary fibrosis associated with systemic sclerosis or a pharma- ceutically acceptable carrier for use in therapy.
[0139] The inventors further provide herein a method for treating a subject in need thereof, typically as described herein. The method of determining whether a patient has a predisposition to fibrosis, is affected by fibrosis, or has non-advanced fibrosis and in subjects identified as having increased fibrosis or a poor prognosis for fibrosis. This invention describes a method for preventing or treating fibrosis, particularly cardiac, skin, pulmonary and / or renal fibrosis. The method typically involves the administration of a CD146 inhibitor, in particular a sCD146 inhibitor or a specific sCD146 inhibitor. D146, or a composition comprising such a CD146 inhibitor or sCD146, is typically Typically, the method includes administering to the subject an effective amount thereof.
[0140] In certain embodiments, the method comprises administering to the subject an antibody, typically an anti-CD1 46 antibody, or a composition (typically a pharmaceutical composition) containing such an antibody, is administered (in an effective amount). The method includes the step of providing the
[0141] Dosage of the diagnostic or pharmaceutical compositions described herein can be determined by one of skill in the art based on the therapeutic objectives, route of administration, target This may be adjusted depending on the tissue, the biologically active compound (disclosed herein), and the like.
[0142] Various protocols may be used to identify CD146-positive cells using anti-CD146 antibodies, CD146 inhibitors, or any other of the above. The compounds may be administered simultaneously or sequentially, or in a single or repeated dose. This may be adjusted by one skilled in the art.
[0143] Diagnostic or pharmaceutical compositions comprising the products of the present invention can be administered to a patient, for example systemically, subcutaneously, spinally, It may be administered intramedullarily, intracerebrally or intradermally to a given target diseased tissue or area. The mode of administration is systemic injection, in particular intravenous or intra-arterial injection, or subcutaneous injection.
[0144] The in vitro, ex vivo or in vivo methods described herein may be used to treat a patient with an agent, typically CD14 6 inhibitors or compositions for the treatment of fibrosis, in particular cardiac, skin, pulmonary and / or renal fibrosis This method typically involves measuring the expression of CD146 in fibroblasts. A first biological sample from a subject prior to any treatment for fibrosis and a second biological sample from the subject prior to any treatment for fibrosis. The method includes comparing the results of the method to a second biological sample from the same subject.
[0145] Also, as used herein, any one or more of the products described herein, typically effective or a therapeutic amount, typically a protein, antibody, inhibitor or composition of (soluble) CD146. and, optionally, a method for administering the product to a subject in need thereof. Means or devices and, optionally, products in connection with the methods described herein and a pamphlet providing instructions for use.
[0146] Preferably, the antibody present in the kit is an antibody that binds to the CD146 protein, typically as described herein. The antibody is directed against one of the proteins, preferably sCD146, described herein. Preferably, it is a monoclonal antibody.
[0147] Typically, the kit also contains a protein, antibody, inhibitor or composition according to the disclosed methods. Includes instructions for use.
[0148] Further aspects and advantages of the present invention are described in the following experimental section, which is incorporated herein by reference in its entirety. The scope of the present invention is illustrative and should not be considered limiting. The references are incorporated herein by reference.
[0149] Experimental section The experiments described herein below show, inter alia: - Two models of severe renal fibrosis induction (a model induced by glomerular basement membrane antiserum and a model induced by glomerular basement membrane antiserum) In a unilateral ureteral obstruction model, CD146 was detected at the glomerular capillary level. The concentration of sCD146 increased in the circulating blood, suggesting its potential to have an effect on fibrosis. However, when CD146 KO mice were used, the effect was greatly reduced, and the animals were treated with anti-sCD 146 is blocked or reversed when antibodies are injected. In a mouse model of myocardial infarction, CD146 was increased around areas of fibrosis and CD146 is increased. -The amount of fibrosis was reduced in CD146 KO animals compared to control animals after myocardial infarction. do. -In aged mice, the development of cardiac fibrosis was significantly reduced in KO-CD146 mice compared to wild-type mice. and decreased. -sCD146 increases the proliferation of renal and cardiac fibroblasts in vitro and promotes myofibroblast proliferation It induces migration into the cells. -sCD146 induces endothelial-mesenchymal transition in renal and cardiac endothelial cells in vitro do. -sCD146 significantly induced miR21, which is frequently associated with fibrosis, in vitro do.
[0150] These results suggest that sCD146 is a typical regulator of fibrosis in various pathologies associated with fibrosis. It is secreted in large amounts in fibrotic human diseases and is involved in the development of interstitial fibrosis by fibroblasts and endothelial cells. Moreover, the phenomenon is related to the involvement of the endothelial cells in the This is prevented or reversed by treating the subject with anti-sCD146 antibodies.
[0151] Example 1 - Endothelium-specific deletion of CD146 protects against experimental glomerulonephritis in mice do Materials and Methods (Mouse strain) CD146-floxed and CD146-KO mice were generated as previously described. , and backcrossed into the C57BL / 6J background for more than 10 generations (Bard In,N,2009), CD146-floxed mice were first transfected with Cre recombinase B6.Cg- expressing the fluorescent protein ZsGreen1 as a reporter for enzyme activation Gt(ROSA)26Sortm6(CAG-ZsGreen1)Hze / J mice (J Then, the CD146 gene was transfected into the 14C-peptide-binding protein 1 (CD146) We generated mice lacking Cdh in endothelial cells, which were kindly provided by Dr. Ralf Adams. 5(PAC)-CreERT2 mouse line and CD146flox-ZsGreen animals By further crossbreeding, it was generated (Wang, Y 2010). CD146 gene The deletions were diluted in corn oil (10 mg / ml solution, 1 mg tamoxifen / injection) Injection of tamoxifen intraperitoneally for three consecutive days induced CD146 allele. The primer for identifying the genotype of the gene was SEQ ID NO: 22: 5'-TCACTTGACAGT GTGATGGT-3' (to detect CD146WT, floxed and KO alleles) Forward primer used in (a), SEQ ID NO: 23: 5'-CCTTAGAAAGCAGG GATTCA-3' (used to detect CD146 WT and floxed alleles) reverse primer) and SEQ ID NO: 24: 5'-CCCAAATCCTCTGGAAGA CA-3' (the reverse primer used to detect the CD146KO allele) That is why.
[0152] (CD146 analysis in various human glomerulopathies) Human renal biopsies were analyzed in a multicenter European Renal cDNA Bank study. k- Kroner-Fresenius Biopsy Bank (ERCB) collection After obtaining informed consent from the patients, approval was obtained from the local bioethics committee. Pre-transplant graft biopsies were used as control kidneys. All RNA was analyzed by immunofluorescence analysis as previously described. The DNA is isolated from glomeruli, reverse transcribed, and linearly amplified (Djudjaj, S., 201 2) Fragmentation, hybridization, staining, and imaging were performed by Affymetrix According to the Expression Analysis Technical Manual The assay was performed using a ELISA kit (Affymetrix, Santa Clara, CA, USA). ChipInspector (Genomatix So), a single-probe-based analysis tool ftware GmbH, Munich, Germany) were used to identify significantly changed Probe-based transcript annotation, total intensity normalization, and microarray validation Randomness analysis (Cohen, CD 2008) and transcript identification were performed. Using expressed TaqMan probes (Applied Biosystems), Human CD146 and GAPDH were detected by qPCR. mRNA expression was measured using standard curves. The results were analyzed by quantification using the following method.
[0153] (Nephrotoxic serum-induced glomerulonephritis) Decomplemented nephrotoxic serum (NTS) was prepared as previously described (Mesnard L2 009;Kerroch M, 2012), 17.5 μl of serum per gram of body weight, The injections were given intradermally on two consecutive days (Days 1 and 2). Two-month-old C57B16 / J females were injected with NTS and then harvested for tissue collection at 4, 7, and 15 days. Six mice were given PBS. was injected and used as a control.
[0154] For the CD146KO protocol, 2-month-old CD146KO female mice and their wild-type mice were used. One live litter was used (n=16 per group). Six mice were injected with NTS and six with PBS. Body weights and urine samples were collected at 0, 4, 8, and 15 days. All mice were sacrificed on day 15 and blood and tissue samples were obtained.
[0155] For the CD146-floxed protocol, 12-month-old female mice were tamoxifen-treated. Six mice were injected with NTS and four with PBS. CD146-floxed ZsGreen mice without the transgene were treated with tamoxifen. Mice were treated with 100 mg / kg / day of NTS and used as controls (n=6 for NTS, n=4 for PBS). Body weights and urine samples were collected on days 0, 4, 8, 12 and 15. Mice were then given blood samples. The animal died 15 days after receiving the drug.
[0156] All animal experimentation procedures were carried out in accordance with the European Union Guide for the Care and Use of Laboratory Animals. This study was approved by the local ethical committee of the French National Institute of Health and Medical Research. Animals were housed at a constant temperature with free access to water and food.
[0157] (Histological and functional parameters) One kidney from each animal was fixed in 4% formalin solution and embedded in paraffin. Four-μm sections were stained with Masson's trichrome stain for histological evaluation of kidney damage. Tubular dilatation was evaluated semiquantitatively using the following scale: 0: no tubular damage; : 1-25% of the analyzed tubules are damaged, 2: 26-50% of the analyzed tubules are damaged, 3: Analysis 5: 51-75% of the analyzed tubules were damaged, 6: >76% of the analyzed tubules were damaged. Crescents were counted and expressed as a percentage of glomeruli showing crescents versus the total number of glomeruli. Sampling was performed in a masked manner on coded slides by two separate investigators. The images were taken at ×200 magnification using an Olympus IX83 photonic microscope. Fibrosis was assessed semiquantitatively at ×200 magnification in paraffin sections stained with Sirius red. Fibrosis was then assessed using a biopsy-based method that can be automatically calculated as the stained area as a percentage of the imaged area. Computer-based morphometric analysis software capable of generating dimensional images (An BUN and proteinuria levels were quantified using an enzyme analysis system (Olympus). Creatinine was measured using a standard method (Konelab automater) and millimolar The concentrations were expressed in grams per millimole and grams per liter, respectively.
[0158] (immunostaining) Immunohistochemistry was performed on 4 μm-thick paraffin-embedded tissue sections. , deparaffinized with 10 mM citric acid, pH 6 at 95°C, was used for antigen retrieval. Sections were permeabilized with 0.1% Triton / PBS. F4 / 80 (AbD Serotec) Antibodies against F4 / 80 and CD3 (Dako) were used. Quantification was performed with at least 10 photographs per specimen at 200x magnification using commercially available image processing. The tissue area was expressed as a percentage of the total tissue area using imaging software (ImageJ; Fiji). Immunofluorescence was performed on 4-μm-thick frozen sections fixed in methanol. Homemade rat anti-mouse), CD31 (Abcam), Claudin-1 (Thermo Scientific), Nestin (BD Pharmingen), Neph rin (Abcam) anti-rabbit and α-SMA (Sigma Aldrich) anti-mouse Antibodies were used. Alexa fluor (Invitrogen) was used for detection of the secondary antibody. Images were taken at ×400 magnification using an Olympus IX83 photonic microscope. I got it at.
[0159] (Quantitative real-time PCR) Total RNA was extracted from one kidney using TRI Reagent (MRC). The residual genomic DNA was verified by measuring the D260:280 ratio and purified by DNase I. treatment (Thermo Fisher Scientific) 1 mg of total RNA was purified using Thermo Fisher Scientific. Maxima First Strand cDNA Synthet The cDNA was transcribed using the hesis Kit according to the manufacturer's instructions. Real-time PCR was performed using SYBR Green PCR Master Mix. oche Light Cycler 480 detection system(R The following programs were developed by Oche Diagnostics, Indianapolis, IN: The incubation was carried out under the program: 95°C for 5 minutes, 95°C for 15 seconds, and 60°C for 15 seconds for 4 cycles. 5 cycles and 72°C for 15 seconds. For quantitative analysis, the experimental genes were Normalization was performed using the DDCT method. Dissociation curves were analyzed to determine that a single product was amplified. The primer sequences are listed in Table 1.
[0160] (Western Blot) Proteins were lysed in RIPA lysis buffer (Santa Cruz Biotechnol CD146 (Epitomics) was extracted from kidney tissue. Western blots for IgG were performed using standard techniques as previously described (Bardin et al. GAPDH (Sigma-Aldrich) was used as a loading control. Used as a roll.
[0161] (statistical analysis) Values are expressed as mean ± SEM. Data were analyzed using Statview software. A one-way analysis of variance followed by Fisher's least significant difference test was used. Error bars represent mean ± SEM for in vivo data and in vitro data. The mean ± SD for all data is presented. Results with P < 0.05 were considered statistically significant. This is what was done.
[0162] [Table 1]
[0163] [result] (CD146 is induced in injured glomeruli) To assess CD146 expression during glomerular disease progression, the inventors performed passive Nephrotoxic serum glomerulonephritis (NTS-GN) was induced in wild-type mice. Animals were treated with NTS. Immunofluorescence revealed weak expression of CD146 in the glomeruli of healthy animals. The expression of CD146 gradually increased from 4 to 15 days in the tubules. The upregulation was observed in the surrounding capillaries and in the damaged glomerulus. This was confirmed by Western blot analysis (Figure 1B and 1C). Mice were protected from nephrotoxic serum-induced glomerulonephritis.
[0164] To evaluate the role of CD146 in GN, we used CD146 wild-type and KO mice. NTS was injected into both the nasal and nasogastric ventricles. Mice were sacrificed 15 days after NTS injection. N resulted in increased body weight after disease induction in WT animals, as expected (Figure 2 A) Therefore, renal function is significantly increased due to proteinuria and blood urea nitrogen (BUN). , and changes in body weight and BUN were observed in CD146KO mice (Fig. 2B and 2C). Furthermore, the increase in proteinuria was significantly lower in these mice. Quantification of tissue lesions by rechrome staining demonstrated that NTS injection significantly reduced the amount of erythropoietin in CD146KO mice. In fact, the CD146 knockout animals showed a marked reduction in damage (Fig. 2D). The poor structural protection results in a significant reduction in crescent formation and tubular dilatation compared to wild-type mice. This was confirmed by the above (Figures 2E and 2F). -Protects against GN-induced glomerular and tubular lesions, thereby improving kidney function protection and reduced proteinuria.
[0165] (CD146KO mice showed reduced inflammation and renal fibrosis after NTS injection) Assessment of inflammatory markers in the kidney by qPCR revealed that IL-1β, TNF-α and IC Induction of AM-1 mRNAs was blunted in CD146KO mice 15 days after NTS injection. Thus, F4 / 80 immunostaining was associated with CD4+ / CD5+ deficiency. We showed a decrease in macrophage infiltration in the renal cortex of 146KO mice (Figure 3D and Figure 3C). 3E). Furthermore, the animals showed reduced CD3 cell infiltration at 15 days (Figure 3E). 3F and 3G). Consequently, renal fibrosis was limited in CD146-deficient mice. The mRNA expression of fibrosis markers, such as TGF-β and collagen III, was significantly increased in CD146KO mice. Quantification of Sirius red staining revealed that the IL-1 signaling pathway was slowed in mice (Fig. 3H and Fig. 3I). We confirmed the reduction of renal interstitial fibrosis in the animals treated with DMARDs (Figure 3J). Our data show that lack of CD146 leads to renal inflammation and renal interstitial fibrosis in NTS-GN. This proves that the limitation of the
[0166] CD146 is increased in the glomerular endothelium during NTS-GN progression. Identifying cell types that overexpress CD146 in injured glomeruli after trauma To this end, the inventors performed colocalization analysis using markers appropriate for glomerular components 7 days after NTS administration. Experiments were performed. CD146 was slightly expressed in the vascular plexus under basal conditions (Figure 1A). After induction with N, overexpression of CD146 mainly colocalized with the endothelial marker CD31 / PECAM. In contrast, CD146 did not colocalize with nestin, indicating that it was associated with podocytosis. The CD146- and claudin-1-specific expression was not detected in parietal cells (Fig. 4C). ) and was not detected in mesangial cells (Fig. 4D). Thus, our data suggest that CD146 is primarily involved in preventing damage after disease induction. This confirmed that the gene was highly overexpressed in the glomerular endothelial cells that had received the gene.
[0167] Endothelial-specific deletion of CD146 protects mice from NTS-GN. To estimate the impact of endothelial CD146 overexpression in the progression of NTS-GN, we performed this study. We generated a CD146-EC-del mouse line. Atamoxifen-inducible VE-cadherin Cre recombinase Mice with CD146flox-ZsGreen mice (Wang, Y, 2010) were By crossing the mice with mice, the deletion of the endothelial cells was observed specifically in the vascular endothelium (Fig. 5A). The specificity of CD146 deletion in tumours was confirmed by immunofluorescence after tamoxifen injection and NT. This was demonstrated 15 days after S administration (Figure 5B) and further confirmed by qPCR (Figure 5C). D146-EC-del mice also showed limited increases in body weight, proteinuria, and BUN. This functional protection was shown by the number of crescents (Figure 6E) in the kidney. Tubular damage (Figure 6F), accompanied by an overall preservation of structure (Figure 6D), was observed after NTS-GN induction. At 15 days, the IL-16 expression levels were dramatically reduced compared to the respective controls. We showed that monocyte infiltration was reduced in the kidneys of D146-EC-del mice (Figure 7 A). Thus, qPCR experiments demonstrated that upregulation of VCAM-1 and MCP1 was completely abolished. The results showed that TGF-β1 and collagen 1 mRNA were significantly increased (Fig. 7B and C). Increased expression of A was blunted in CD146-EC-del mice compared with control kidneys. (Figure 7D and Figure 7E). These data suggest that endothelial overexpression of CD146 is a potent This proves to accelerate the progress of Experimental GN.
[0168] (CD146 transcript numbers are increased in human glomerulopathies) CD146 mRNA expression was measured in patients with diabetic nephropathy (DN, n=7), minimal change nephrosis (MDN), and syndrome (MCD, n=5), IgA nephropathy (IgA, n=27), focal segmental glomerulosclerosis ( FSGS, n=10), membranous nephropathy (MGN, n=21), lupus nephritis (SLE, n= 32) and from kidney biopsies of patients with rapidly progressive glomerulonephritis (RPGN, n = 23). Microdissected glomeruli were analyzed. Compared to control biopsies (n=6), damaged glomeruli Glomeruli showed a clear upregulation of transcription of CD146 transcripts (FIG. 8).
[0169] [Consideration] Various chronic inflammatory diseases are associated with a disruption of endothelial function and junctional integrity (W uthrich RP, 1990). Defects in endothelial junctional organization are a cause of chronic kidney disease. Indeed, in biopsies from patients with nephropathy of several etiologies, the inventors We have shown that high expression of endothelial CD146 is associated with intraductal proliferation, proteinuria, and inflammation. We have previously reported that CD146 expression is involved in the inflammatory process (Daniel L, 2005). The increase in IL-1 levels was consistent with the morphometric changes in the kidney during the progression of chronic renal failure and was supported by CD146. These results suggest that the function of the retained junctions may be altered in this pathological setting. However, the pathological significance of this overexpression remains unclear. In the experiments described herein, increased expression of CD146 indicates that its loss is a renal It protects the kidneys from immune attack and prevents serious kidney damage, which may promote kidney disease. The inventors have demonstrated that CD146 is a novel inhibitor of the initiation and progression of glomerulonephritis. This has proven to be a therapeutic target.
[0170] In this study, CD146 was expressed in the renal microcirculation, primarily in damaged glomeruli, and was associated with disease progression. CD146 is also overexpressed in the proximal tubules at later time points. In our experimental model, the onset of the disease was observed in the endothelial cell line (Fig. 1A). Overexpression of CD146 in the glomerular compartment is associated with renal failure, proteinuria, and weight gain. CD146KO mice were protected from these changes. CD146 has been reported to be expressed on myeloid cells in mice (Despo et al., 2013). ix, N, 2008). Staining experiments showed that CD146 is mainly overexpressed in the injured endothelium. Thus, the inventors identified a specific role for endothelial CD146 in NTS-GN. To distinguish between glomerular injury and endothelial injury, we generated CD146-specific endothelial knockout mice. This clearly demonstrates a key role for endothelial cells in controlling both endothelial cell proliferation and interstitial inflammation. The results indicate that endothelial CD146 is involved in the regulation of monocyte transendothelial migration in vitro. This is consistent with previous research by the inventors that proves this (Bardin, N, 2009). Upon stimulation with tumor necrosis factor-α, the expression of CD146 was increased in human umbilical vein endothelial cells (HUVECs). ) at both cell junctions and the apical membrane, further contributing to the transmigration of monocytes from the endothelial monolayer. Similar results were reported more recently in a mouse model of multiple sclerosis, in which We demonstrated that targeting endothelial CD146 inhibits neuroinflammation and lymphocyte extravasation at the blood-brain barrier. This was reduced by limiting the amount of exposure to radiation (Duan, H.; 2013).
[0171] Another interesting finding was that renal fibrosis was significantly increased in CD146KO and CD146-EC-del mice. This observation was carried forward in a model of crescentic GN, a rare disease in humans. Although renal fibrosis has been reported in various types of kidney disease, it is unclear whether renal fibrosis is the product of a common progression of all kidney diseases. This is of particular interest and is a high predictor of progression of chronic kidney disease (CKD). (Rockey, DC 2015). The inventors found that endothelial CD146 is involved in the expression of endothelial cells. We believe that endothelial cells play an important role in controlling the fibrotic process by responding to activation of the endothelium. Endo-MT is a key regulator of fibrosis in various mouse models of experimental nephropathy. have been proposed to contribute to the accumulation of activated fibroblasts and myofibroblasts in the kidney. (Zeisberg, EM, 2008). This suggests that low expression of CD146 The reduction in fibrosis can be partially explained by the reduction in Endo-MTs when the IL-1 receptor is activated. However, more recent studies have demonstrated the contribution of the Endo-MT program to the development of renal fibrosis. The contribution was shown to be moderate (LeBleu, VS, 2013). For example, a role for CD146 has been described in epithelial-mesodermal transitions in other tissues. As previously reported, it plays a role in inducing cell activation, a key event in metastasis. It is possible (Zeng, Q., 2012, Liang, Y.K. 2017). The inventors In the present study, soluble CD146 (sCD146) released by activated endothelial cells was found to be involved in the proliferation and proliferation of fibroblasts. Stimulates cell proliferation and transition to a myofibroblast phenotype, promoting renal extracellular matrix deposition and fibrosis. GN is the second most common cause of end-stage renal disease (ESRD) worldwide. It is recognized as a high cause of cancer (Chadban, SJ, 2005). Despite immunosuppressive therapy, rapidly progressive nephritis leads to irreversible CKD and frequently ESRD. This can lead to chronic kidney damage. Glomerular damage, tubulointerstitial inflammation and fibrosis in GN. Given the need for a therapeutic target to suppress CD1 in renal inflammatory injury, the inventors To investigate the role of 46 in human glomerulopathy, we developed a powerful experimental tool that has several characteristics. In fact, the injection of sheep serum rich in immunoglobulins against glomerular antigens was This leads to infiltration of immune system cells into the kidney, followed by severe glomerular damage and rapid loss of kidney function. (LuqueY.,2017;El Machhour F.,20l5;Mesnar d L.,2014;Toubas J.,2011;Mesnard L.,2009 ) This is a sign of rapidly progressive renal disease, as the mice die within 4 weeks of disease induction. It is a robust model (Kerroch M., 2012; Kavvadas 2017 Therefore, the advantage of this GN model is that it can rapidly inhibit the pathogenic process that causes immune-mediated nephritis. Several potential diagnostic tools that can be used to determine the severity of the disease This will have a major impact on both the genetic prevalence and clinical treatment perspectives. Therefore, it has important clinical significance (Fu Y, 2007). Several mediators, including inflammatory cytokines, adhesion molecules, surface receptors, and extracellular matrix proteins, mediate C It has been shown to play a critical role in mediating the inflammatory response in KD (Tang W W,1994;Le Hir M.,1998;Schwarting A.,1998 ;Kitching AR,1999;Karkar AM,2001;Kishimo to T.2005;Henique C.,2016;Prakoura N.,201 7) Thus, the main findings of our study are that CD146 deletion is a potent inhibitor of CD146KO and C This GN model is consistent with the slowing of disease progression in both D146-EC-del mice and D146-EC-del mice. The therapeutic potential of specific inhibitors of CD146 is promising. The researchers' interest stemmed from the discovery that this junction molecule was expressed in glomeruli in biopsies from patients with different types of GN. , and was enhanced by overexpression compared to healthy controls (Figure 8). The results showed that the renal endothelium controls invasion of all compartments, not only the glomerulus but also the tubule. This supports a key role for endothelial CD146 in the progression of GN. The authors conclude that this interface molecule plays a key role in preventing the progression of acute GN to chronic kidney disease. This has proven to be an effective treatment strategy.
[0172] The inventors also examined the expression of CD146 in kidney sections in vivo by immunohistochemistry. The study also demonstrated that sCD146 secretion was expressed in the plasma of UUO (unilateral ureteral obstruction) animals. The results were quantified by lisa method in comparison with sham-operated animals (Figure 29). 146 was significantly increased in kidneys with UUO compared with the contralateral kidneys, and and sCD146 were significantly increased in UUO animals compared with sham-operated animals. This indicates that:
[0173] The effect of UUO was observed on the expression of type I collagen, type III collagen, and fibronectin. The results (Figure 30) showed that UUO increased the expression of such proteins. Interestingly, anti-sCD146 antibody induced inflammatory responses before or 1 week after UUO. Treatment increased collagen and fibronectin expression compared to control IgG. This suggests that antibody treatment interferes with the deposition of collagen and fibronectin. This indicates that.
[0174] The effect of UUO was observed on the expression of a-SMA. The results (Figure 31) showed that UUO Interestingly, the expression of SMA was increased in the rats before and one week after UUO. Treatment with anti-sCD146 antibody reduced the expression of a-SMA in mice compared to control I Compared to gG, the antibody treatment prevented fibronectin activation. This indicates that.
[0175] The effect of anti-sCD146 treatment was examined by measuring the activity of a-SM in human kidney fibroblasts in culture (in vitro). The results (Figure 32) showed that the anti-sCD146 Treatment with the antibody (500ng / ml) increased sCD146 expression, as observed with sCD146. The results showed that the inhibitor inhibited the induction of increased expression of a-SMA and vimentin mRNA. show.
[0176] Example 2 - Establishment of cardiac fibrosis by CD146 / CD146s expression in a myocardial infarction model Associated with an increase The inventors have demonstrated in vivo in animals that the establishment of cardiac fibrosis is consistent with that in a myocardial infarction model. The inventors also demonstrated that CD146 / CD146s expression is associated with increased expression of CD146 / CD146s. In vitro, CD146s promotes the differentiation of cardiac fibroblasts into myofibroblasts by TGF-β Therefore, CD146 / CD146 s represents a novel therapeutic target aimed at the process of limiting and / or reversing cardiac fibrosis. It becomes.
[0177] Materials and Methods I In vivo testing The role of CD146 / CD146s was investigated in two mouse models of cardiac fibrosis. . -The first model of cardiac fibrosis induced by myocardial infarction - A second model of chronic cardiac fibrosis in aged animals
[0178] a) Myocardial infarction-induced cardiac fibrosis model This first model was developed by Dr. Francesca Rochais (CR, French National The study was established in collaboration with the team at the Institute of Health Sciences, UMR S 910. Anesthesia is achieved by intraperitoneal injection of a mixture of amine, xylazine and atropine. The animal is intubated and placed under artificial ventilation. The animal's chest is opened, the pericardium is opened, and the left descending coronary artery is exposed. Cardiac ischemia was visualized by bleaching the left ventricular apex below the ligation point. The animal's pericardium is closed and the animal is placed in a recovery cage. The survival rate of things is, on average, 50%.
[0179] All treatments are performed on 12 week old C57BL6 females divided into two groups. C57BL6-Sham mice (n=3): Animals were subjected to thoracotomy without ligating the coronary artery. Before the surgery, you will be anesthetized and intubated. C57BL6+MI mice (n=3): Animals were subjected to a complete surgical procedure to include myocardial infarction. The installation will be carried out.
[0180] All mice (SHAM and MI) were sacrificed after 21 days. Animals were They were anesthetized with 500 mg / kg, weighed, and an intracardiac blood sample was withdrawn before being killed by cervical dislocation. Remove the heart and tibia of the animal.
[0181] b) Chronic cardiac fibrosis aging model The experiment was performed in mice expressing CD146 compared with C57BL / 6 mice expressing CD146 (n=5). 24-month-old female transgenic C57B1 / 6 mice that do not express CD146 (CD146-KO; n = 100) 5) After sacrifice, the heart of each animal is removed. The heart is then subjected to histological examination. (n=3) and prepared for immunohistochemical analysis or RNA or protein extraction ( n=1), quench at 80°C.
[0182] c) Cardiac function tests Cardiac function of the animals was monitored using Doppler echocardiography (VisualSo The evaluation was performed using the nicsVevo2100, 550D probe. From the images captured by the camera, the longitudinal (long axis) and transverse (short axis) directions are sequentially The following parameters, diastolic volume, systolic volume, and systolic ejection fraction were calculated. Measure.
[0183] d) Histological and immunohistochemical examinations Tissue preparation: The harvested hearts were rinsed with cold PBS solution and first cooled in liquid nitrogen. Cryo-fix in isopentane and store at -80°C. Serial 7 μm thick sections were cut into four sections. Horizontally dissect the heart using a cryostat so that the ventricles are visualized in histological sections. Cut with a surface.
[0184] Sirius Red staining: Sections were fixed in formaldehyde (diluted 4% in phosphate buffer) for 3 min. The sections were immersed in Sirius red for 1 hour. Afterwards, the sections were stained with acetic acid solution (0.5% in double distilled water), dehydrated in an alcohol bath, and then quenched. Clear with silane and mount with resinous mounting medium (Entellan). Slides are then immersed in Oligosaccharides. Observed with an Olympus BX-40 microscope and photographed with an Olympus DP-21 camera do.
[0185] Quantification is performed using ImageJ software. After removing the vascular structures, the collagen The fraction of the area occupied by collagen stained red (%) was calculated by dividing the area occupied by collagen stained red (%) by the fraction of the area occupied by collagen stained red (%). is expressed by relating it to the total tissue area.
[0186] In total, three sections were stained for each animal (four animals per group), each Only the left ventricle of each animal is photographed in four fields of view (×20) and quantified.
[0187] Determination of myocardial cell size using wheat germ agglutinin (WGA) After rehydration, tissue sections were incubated for 45 min in a solution containing WGA and DAP1 (1 / 5000). The slides are incubated at 4°C for 10 min and rinsed before mounting in aqueous media. The images were then analyzed using ImageJ software. Three sections were stained for each animal (three animals per group), and each Four fields of view (×20) were photographed from the left ventricle of the animals, and quantification was performed. The area of cells was determined by the area where the nucleus was located in the center. The size of the cells placed on the plate is determined by measuring the size of the cells.
[0188] (immunohistology) Sections are thawed and then fixed in cold acetone for 10 minutes. Conventional immunohistochemical testing was performed on sections with antibodies generated in other species. It consists of several steps. Blocking endogenous peroxidase activity: Sections are diluted with methanol and Incubate in 0.6% H2O2 for 15 minutes. -Sections were incubated for 20 min at room temperature with normal serum from the species in which the secondary antibody was generated (in 5% PBS). Incubate for 1 min to block non-specific staining.
[0189] Sections were incubated in a solution containing the primary antibody for the dilution and incubation time specified in Table 2. Incubate.
[0190] [Table 2]
[0191] The sections are then incubated in a secondary antibody solution. Use antibodies (Table 3).
[0192] [Table 3]
[0193] The sections were incubated for 30 min with a solution containing avidin-biotin complex (Vector) Detection of peroxidase is performed using DAB (Sigma). Sections were counterstained with hemalum (Mayer) and then dehydrated and mounted (Entel). lan).
[0194] For sections in which the primary antibody was raised in mouse, a commercially available kit (Vector Mouse IgG was generated in mouse tissue using mouse IgG (MOM). Neutralize to reduce background noise associated with the use of antibodies.
[0195] e) Molecular biological analysis The hearts are placed on ice and then opened to remove any blood clots that may have formed in the ventricular cavities.
[0196] (RNA extraction from tissues) The obtained tissue (100 mg) was absorbed with 1 mL of QIAzol and then incubated for 30 seconds. Homogenize on ice using a Polytron. Add 200 μL of chloroform to the homogenizer. Add the supernatant to the flask, shake vigorously and centrifuge the sample at 12000g for 15 minutes. Collect the RNA and precipitate it by adding 500 μL of isopropanol. The NA is pelleted by centrifugation at 12000 g for 10 min at 4° C. The NA pellet was washed with 75% ethanol and then rinsed with 20 mL of RNase-free water. The amount of RNA was measured using a spectrophotometer (NanoDrop) at 260 nm. The measurement is performed using
[0197] (Reverse Transcription) Reverse transcription was performed using High Capacity cDNA Reverse Transcription Deoxyribonucleic Acid (Deoxyribonucleic Acid) was performed using the iption kit (Applied Biosystems). Nucleotide triphosphates, oligo(dT), random primers and MultiScrib e H2O to which a mixture containing reverse transcriptase is added 500ng of RNA absorbed in 10μL Then, do it.
[0198] The mixture was incubated at 25°C for 10 min in a Mastercycler Gradient device. The reaction was incubated at 4 °C for 120 min and then at 37 °C for 120 min. The resulting cDNA is inactivated at 85°C for 1 min. The resulting cDNA is immediately frozen at -80°C.
[0199] (Real-time polymerase chain reaction (qPCR)) PCR, Power SYBR Green PCR Master Mix Ki t (Thermo Fisher Scientific). First, 10 ng of cDNA was mixed with 250 nM of left and right primers targeting the gene of interest (Table 4) Taq polymerase, deoxynucleotide triphosphates, and SYBR Green Add 12.5 μL of buffer containing 10 mM NaCl and add to the mixture containing 10 mM NaCl.
[0200] [Table 4]
[0201] Amplification was performed using a StepOnePlus thermocycler (Thermo Fish The samples were then incubated at 95°C for 5 min (denaturation), 95°C for 10 s (denaturation), and 10 s (denaturation). (primer hybridization), and 60°C for 30 seconds (polymerization). After each cycle, the fluorescence is read. After determining the Ct value, , to determine the relative expression of each of the genes under study.
[0202] II. In vitro testing (Maintenance and stimulation of cardiac fibroblasts) Human cardiac fibroblasts (HCF) (PromoCell) were cultured using Fibroblast G rowth Medium 3 Supplement Pack (PromoCel The HCFs are grown in a controlled atmosphere at 37°C in a 100°C hood (100°C) hood (150°C). Can.
[0203] For stimulation, fibroblasts were cultured at 30,000 cells / cm 2 The cells were seeded on complete medium at a density of After 24 hours of adhesion, the cell culture medium was replaced with a medium (minimal medium) containing no growth factors for 4 hours. Replace.
[0204] This medium was then diluted with 25, 50, 75 or 100% CD146s for proliferation studies. Minimal medium supplemented with 2.5, 5, or 10 ng / mL TGF-β Replace.
[0205] (Cell proliferation) Cell proliferation is determined using a proliferation kit (BrdU Assay, Roche). Incubate with anti-BrdU antibody diluted 1 / 100 in diluent for 90 minutes at 37°C. After removing excess antibody and rinsing, anti-BrdU specific peroxidase-conjugated The secondary antibody is incubated for 30 minutes at room temperature and then removed. Detection is performed using an enzyme substrate. The reaction is carried out by adding 50 μL of 0.1 M H2SO4 solution. The staining intensity and the percentage of BrdU incorporation were determined by spectrophotometric analysis at 450 nm. The results were compared with the results of culture wells containing no cells but loaded with the same amount of BrdU. The growth rate is then calculated by subtracting the background noise observed in the experiment. Calculate the percentage of each condition. For each experiment, calculate 6 The results obtained for the wells are averaged.
[0206] (RNA Expression) Total mRNA was extracted using a purification kit (RNeasy Mini, Qiagen). After elution, the mixture was eluted in 30 μL of RNase-free water. The amount of RNA was measured using a spectrophotometer ( The RNA was measured at 260 nm using a NanoDrop. Convert tissue RNA to cDNA following the same protocol using ELISA kits. Gene Expression Studies by real-time PCR from 10 ng of cDNA (Table 4).
[0207] (Protein Expression) The cells were incubated at 4°C in 10 mM Tris-HCl (pH 8), 1 mM EDTA, 150 mM Buffer solution (P The resulting cell lysate was dissolved in a centrifuge (Thermo Scientific). The mixture is centrifuged at 15,000 g for 10 min at 4° C. The supernatant containing the solubilized protein is collected. To do this, the amount of protein was adjusted to 1 mg / mL diluted in the lysis buffer used during sample preparation. The determination is made using a standard curve of bovine serum albumin (BSA) prepared from BSA solution.
[0208] The samples and standards to be evaluated (25 μL) were deposited in a 96-well plate and Add 200 μL of A reagent (BCA Assay Kit, Pierce). Read at 550 nm and determine the protein concentration of the sample of interest using calibration standards. do.
[0209] The samples are then used in Western blot experiments. An aliquot containing 30 μg of protein was diluted with 4× Laemml containing reducing agent (Invitrogen). After absorption with i-buffer, electrophoresis gel (NuPAGE 4-12% Bis-Tr Heat at 75°C for 10 minutes before depositing onto the gel (Invitrogen). After electrophoresis of the samples, the proteins were transferred to a nitrocellulose membrane (iBlot 2, In The membrane was then transferred to a dry well (Vitrogen) in 0.1% Tween for 45 minutes. Block with Tris buffer containing 20 (TBS-T) and 4% BSA. Primary antibodies (Table 5) diluted in TBS-T were hybridized for 12 h at 4°C, followed by Rinse with TBS-T for 3 x 10 min. Incubate with HRP-conjugated secondary antibody (TBS-T) for 1 h. After rinsing, the HRP activity was detected using a chemiluminescent substrate (ECL, Pierce ) was used for detection. A standardization protein (β-thiol) whose expression was not affected by the experimental conditions was used. The results can be expressed semiquantitatively after standardization of quantification using antibodies directed against IgG (tubulin). The emitted light is captured by a camera (G:BOX). The target protein is detected by a black The resulting signals are visualized as colored bands on a white background. Quantification was performed using Image Lab Software version 4.1. (Table 5).
[0210] [Table 5]
[0211] (Immunofluorescence) Cells are fixed in 70° C. ethanol for 5 minutes at 4° C. and then rinsed with PBS. Blocked in 5% BSA in PBS for 1 hour, then primary antibody diluted 1 / 50 (anti-α-SMA, Dako-0851) and fluorescent molecule (Alexa Fluor 488) Incubate with secondary antibody (anti-mouse antibody) conjugated with PBS for 1.5 hours. Between each step, rinse with 50 mL of ethanol was performed. Cells were then nucleated before being examined under a fluorescent microscope. Aqueous medium containing stain (ProLongMountant with DAPI, Inv The mixture is sealed in immunogen.
[0212] [result] I. Study of CD146 / CD146s expression in two models of cardiac fibrosis The aim of the first part of this study was to investigate the expression of CD146 / CD146s during cardiac fibrosis. To this end, the inventors investigated the mechanism of cardiac fibrosis induced by myocardial infarction. The present study relied on models of chronic cardiac fibrosis observed in aged animals.
[0213] a) Cardiac fibrosis induced by myocardial infarction (Development of cardiac fibrosis) Sirius red staining (FIG. 13B) revealed a fibrotic zone located at the periphery of the left ventricle in the animals. The densest zone of collagen deposition (fibrous zone) was located in the infarct zone. The fibrotic zone (zone or fibrotic zone) no longer contains cardiomyocytes. In this study, the deposition was interstitial and occurred in the border zone between cardiomyocytes in the left ventricle of MI animals. extends gradually into region ("BZ" or "BA").
[0214] (Expression of mRNA encoding CD146) Analysis of CD146 RNA expression (Figure 13C) was performed by RT-PCR in the infarct / fibrosis zone. From the microdissected tissue of the endothelium zone ("IZ" or "FZ"), the tissue immediately proximal to this zone ("BZ ") and then to the distal / remote zone ("DZ" or "RZ"). The results are compared to those obtained using RNA extracted from the left ventricle of SHAM animals. Overall, CD146 expression was significantly higher in the left ventricle of MI animals compared to SHAM individuals. Analysis of each cardiac zone showed that CD146 expression was increased in In particular, there was a significant increase of 3-fold in the tissue zone immediately proximal to the infarct zone (BZ). This indicates that
[0215] (CD146 immunodetection) In SHAM mice, CD146 staining was uniform and concentrated at the periphery of cardiomyocytes. In mice with MI, CD146 expression was significantly increased in the fibrosis zone (Fig. 14A and Fig. 14B). Within the zone, the vascular structures present in this zone are few and are still associated with each other (Figure 14, Conversely, CD146 expression was significantly higher around fibrotic areas (FA or BA). Very common (Figure 14, "BA"). This perifibrotic staining is observed at the tissue scale. The staining was increased in the border zone and in distant areas ("DZ" or "RA"). This markedly decreased CD146 expression, revealing a gradient in CD146 expression (Figure 14, High magnification observations showed that at the periphery of the fibrotic zone, CD146 expression was localized to myocardial cells. The BA and BZ are located in the cytoplasm of the myocardial cells (Figure 14, "BA" or "BZ") and are located at the periphery of the myocardial cells. These results show that the expression of IFN-γ is substantially increased in cells that have IFN-γ expression.
[0216] (Serum assay for CD146) A first serum assay for CD146 (Figure 14B) was performed in SHAM and MI mice (n The preliminary results showed that soluble These results show that CD146 was increased in animals with MI-induced cardiac fibrosis. The results of 1 remain to be confirmed in new cohorts of animals.
[0217] b) Aging cardiac fibrosis model (Development of fibrosis) Sirius red staining (Figure 15, e) was performed on a section from the heart of an aged (24-month-old) mouse. The color of the blood vessels in the blood vessels was significantly increased compared to that of young mice (3 months old). There is increased periductal and interstitial collagen deposition.
[0218] (CD146 immunodetection) In an age-related (24-month-old) cardiac fibrosis model, CD146 expression (Fig. 15, f) was significantly increased in 1 The increase in CD146 was consistent with that observed in 2-week-old SHAM animals. They are found both within the alveoli and within the cells located around their periphery.
[0219] II. Role of CD146 in the development of cardiac fibrosis We used laboratory-produced animals that do not express CD146 (CD146-KO). We demonstrate the role of CD146 in the development of cardiac fibrosis during aging. The results were compared to a group of WT animals (n=4) compared to 1 year-old female CD146KO animals (n=4). I did.
[0220] (Cardiac Fibrosis) In WT animals, Sirius red staining revealed that collagen accumulated between cardiomyocytes and It is clear that the CD146 knockout cells are isolated from each other (Figure 16A, a). Observation of biological sections revealed much less collagen deposition and individualization of cardiomyocytes. It is clear that the results are not consistent (Figure 16A, b). Quantification of Sirius Red (Figure 16A, b) 16A, c) Collagen deposition in CD146KO animals was significantly decreased compared to WT animals. The results confirmed that the number of animals from each experimental group was reduced by approximately 50%. Type I collagen RNA expression was confirmed by RT-PCR analysis from the hearts of the mice. It has been done.
[0221] (Size of cardiomyocytes) WGA staining (Figure 16B) specifically stains the cell membrane, and then the cell Our results show that the size of myocardial cells located in the left ventricle of WT animals can be determined. These results show that the cells in the CD146KO animals were larger than those in the CD146KO animals (Fig. 16B, a). This observation has also been confirmed by quantifying the area of stained cells (Figure 16B). , b). Thus, in WT mice, the cardiomyocyte area was 100%. In CD146KO mice, This is approximately double the quantified area, reflecting a marked reduction in cardiomyocyte hypertrophy in this animal. is.
[0222] III. The role of CD146 in the acquisition of myofibroblast phenotype Increased CD146s and cardiac fibrosis associated with lack of CD146 in MI animals Based on the observation that CD146s reduces myofibroblast proliferation, the present inventors have demonstrated that CD146s plays a role in myofibroblast proliferation. We hypothesized that the mechanism underlying this is the recruitment / differentiation of resident cardiac cells (myoFBs). We therefore tested the effect of CD146s during differentiation of cardiac fibroblasts into myoFBs. Ta.
[0223] To this end, the inventors investigated the myoFB phenotype (proliferation, α-SMA expression and fibrosis). The effect of CD146 on expression markers associated with cellular matrix protein (CMP) In all these experiments, fibroblasts were treated with myoF as a control TGF-β. This was done using a known inducer that activates B.
[0224] a) Effect of CD146s on cell proliferation of cardiac fibroblasts (HCFs). The effect of increasing the amount of CD146 was examined on the proliferation of cardiac fibroblasts (Figure 17A The results show a significant, dose-dependent increase in cell proliferation. A proliferation-promoting effect was observed with CD146s at 50 ng / mL. This CD146-induced increase in proliferation was due to the fact that the cells were This is equivalent to that observed when stimulated with 100 mg / mL.
[0225] b) Effect of CD146s on a-SMA expression Regulation of α-SMA expression was measured by stimulating HCF with 50ng / mL of CD146 for 48 hours. In response, we investigated.
[0226] Semiquantitative analysis of RNA expression levels showed that CD146s significantly increased the expression of α-SMA (n=4). The cells were then treated with 5 ng / mL TGF-β to induce a 2.5-fold overexpression of β-lactamase inhibitors. This is comparable to the induction observed when the cells were stimulated with 100 μg / mL of β-lactam 2 (Fig. 17B). This correlates with the α-SMA protein expression analysis performed by / mL also induced a 2.5-fold increase in α-SMA protein expression levels (Figure 17C ).
[0227] Indirect immunofluorescence using an antibody directed against α-SMA revealed that CD146 50ng / This increase in α-SMA expression induced by mL may be a signaling pathway that mediates smooth muscle actin nephropathy. The actin network of smooth muscle is associated with the establishment of a network of HCFs. The α-SM infiltrates the cytoplasm of the endothelial cells and its organization is observed in response to stimulation with TGF-β. We show that the results are comparable to those of the A network.
[0228] c) Effect of CD146s on the expression of matrix proteins Semiquantitative expression of RNAs encoding two of the matrix proteins expressed by myoFB RT-PCR analysis demonstrated that CD146s inhibits the synthesis of fibronectin and type I collagen. (FIG. 17E), similar to that observed in response to stimulation with TGF-β. It has been shown that it induces an increase
[0229] d) Effect of CD146s on the expression of TGF-β Associated with a myofibroblast phenotype in response to stimulation of HCFs with CD146s The increased expression of markers associated with TGF-β expression (Figure 17F) indicates that this effect is the result of induction of TGF-β expression. The present inventors therefore conducted research into the mechanism required for this effect. We began by studying the effect of TGF-β on CD146 expression. Results (n=2) showed that CD146s at 50ng / mL induced a 2-fold increase in CD146 expression. This indicates that it induces
[0230] [Consideration] Cardiac fibrosis occurs naturally in response to certain forms of heart disease, such as myocardial infarction, or through aging. At present, there is a lack of effective treatments for cardiac fibrosis. Therefore, this objective is a major public health challenge. We investigated the role of CD146 / CD146s in the expression of IL-1 and its use as a therapeutic target. The inventors conducted a study to investigate the effect of IFN-γ on the aging and myocardial infarction in two mouse models. In vivo, and in vitro, in human cardiac fibroblasts (HCFs), CD146 / CD146s We were able to show that indeed influences the development of cardiac fibrosis.
[0231] Our results show that in MI and aged animals, cardiac fibrosis is associated with overexpression of CD146. In animals with MI, cardiac fibrosis was localized in the apex and extended to the left ventricle. However, CD146 overexpression was not observed in the infarct zone, but rather with distance from this zone. This is accompanied by an increase in the proximal zone with a gradient of expression that decreases gradually from the nucleus to the proximal zone. Overexpression of CD146s is accompanied by an increase in the secretion of CD146s. , which is generated by a mechanism that cleaves membrane-bound CD146 (Bardin et al., 2003). is known, which explains the simultaneous increase in the two types.
[0232] Furthermore, the inventors found that the development of cardiac fibrosis was also associated with overexpression of CD146. This was observed in the aging model. showed increased interstitial collagen deposition in mice, which correlated with CD1 expression across the left ventricle. The use of CD146-KO animals in this model is These results were confirmed by showing a reduction in interstitial collagen deposition. Moreover, CD146-KO animals showed a marked reduction in cardiomyocyte proliferation, which is seen in SHAM mice. In the aging model, the inventors found that hypertrophy was significantly reduced during the emergence of chronic cardiac fibrosis. We have confirmed the activity of CD146 / CD146s.
[0233] Cardiac fibrosis is a process that takes time to establish. In fact, reparative fibrosis (rfibrosis) eparative fibrosis is a series of three interdependent stages: the inflammatory stage The first stage is the proliferation stage, and the last stage is the maturation stage. When stimulated with sCD146, cell proliferation increased and myofibroblast differentiation was induced. Moreover, this stimulation is a known factor in the differentiation of fibroblasts into myofibroblasts. This is identical to that obtained during stimulation with TGF-β. Moreover, CD146s The markers that characterize myoFBs, α-SMA, fibronectin, and type I collagen, Such overexpression also induces increased expression of inflammatory cytokines after stimulation with TGF-β. All these results are consistent with those seen in the literature. These results indicate that the myoFBs are involved in the differentiation of myoFBs.
[0234] Our preliminary results also show that CD146s can increase TGF-β Stimulation by CD146s Subsequent studies of TGF-β expression have provided insight into one of the potential molecular mechanisms and have demonstrated that TGF-β and It will be possible to determine whether CD146s has an additive or synergistic effect.
[0235] Other processes that give rise to myofibroblasts, in particular the endothelial-mesenchymal transition (EndoMT) process, Future in vitro studies will explore the differentiation of endothelial cells into mesenchymal cells by IFN-γ. Therefore, we investigated the effect of CD146 on this cellular process by comparing it with endothelial markers (PECAM-1, Expression of mesenchymal markers (α-SMA, vimentin, fibroblasts, etc.) The study will be carried out by comparing and analyzing the .
[0236] At present, there is a lack of effective treatments for controlling cardiac fibrosis. The specification indicates that CD146 / CD146s activity is a therapeutic target. An antibody specific for soluble CD146 has been generated by the inventors. It has a blocking effect, i.e. it can suppress the effect of CD146s.
[0237] Example 3 - Various pro-angiogenic variants of soluble CD146 inhibit shedding and replacement By splicing, secretion by endothelial cells: properties and involvement in fibrosis Soluble CD146 is involved in physiological and pathological functions, and is primarily involved in regulating angiogenesis. Therefore, the inventors have determined that 1 / sCD146 is produced in endothelial cells. Shedding mechanism of long and short CD146 isoforms 2 / The potential existence of splice variants of sCD146; 3 / Their respective functions Investigating the functions of these proteins, particularly in the regulation of angiogenesis and fibrosis, and their involvement in systemic sclerosis did.
[0238] [method] (cell) Endothelial colony forming cells (ECFCs) were cultured in endothelial EGM-2 MV medium as previously described. HUVECs were obtained as previously described and cultured in EGM2 medium (Delorme B et al., 2005). MEF (mouse embryonic fibroblasts) were cultured in vitro for 13 days (Kaspi et al., 2017). Embryos from CD146KO or WT mice were isolated and cultured as previously described (X u J., 2005).
[0239] (Cell proliferation assay) Experiments were performed as previously described (Stalin et al., 2013).
[0240] (Endothelial cell tube formation in spheroids) Formation of spheroid experiments was performed as previously described (Korff T. et al., 2001).
[0241] (Co-immunoprecipitation experiment) Experiments were performed as previously described (Stalin et al., 2016).
[0242] (b-catenin / TCF transcription assay) Luciferase assays were performed as previously described ( Kaspi et al., 2017 ).
[0243] (Chorioallantoic membrane assay) Chorioallantoic membrane of chick embryo assay (CAM) was performed using a previously described protocol (Bec Kers et al., 1997).
[0244] (Lipid raft preparation) Lipid rafts were identified by sucrose density gradient centrifugation of non-ionic detergent-treated cells. and isolated as previously described ( Tellierei et al., 2006 ).
[0245] (Animal models and histological analysis of systemic sclerosis) Female CD146KO mice (11–16 weeks) were cultured as previously described ( Kaspi et al., 201 7), were treated with subcutaneous bleomycin and compared with one WT mouse from the litter.
[0246] Mouse skin sections were fixed in 4% formalin and embedded in paraffin. As previously described (Kaspi et al., 2017), a stereological method was used using the Merz grid. The quantification was carried out using the method.
[0247] (siRNA experiment) We generated siRNAs designed to suppress the expression of various isoforms of sCD146. A control siRNA was also used in each experiment. Cells were incubated with Silence 100 μg / mL as described by the manufacturer (OZ-Biosciences). The cells were transfected using the magmagnetofection kit. As a result, approximately 80-95% of protein expression was suppressed. Shown in 6.
[0248] [Table 6]
[0249] (RNA isolation, reverse transcription and real-time PCR) Total cellular RNA is isolated from cells and reverse transcribed into cDNA, and the resulting cDNA A was subjected to qPCR. The forward and reverse specific primer sequences are shown in Table 7.
[0250] [Table 7]
[0251] (Western blot analysis) The membrane was incubated with specific primary antibodies (7A4 1 / 3000, actin 1 / 5000, Tac e and ADAM10 1 / 1000, I1O-sCD146 and I5-13-sCD14 6 1 / 250) and then a secondary antibody bound to peroxidase. The antibodies were revealed using ECL substrate (Pierce).
[0252] (Quantitative Flow Cytometry) Membrane expression levels of various isoforms of CD146 were measured using antibodies or isotype-specific Matched control antibodies were conjugated to fluorescent dyes (10 μg / ml) for 1 h at 4°C. After washing, samples were analyzed by flow cytometry (Ga lliosTM Flow Cytometer, Beckman Coulter, V The results were then analyzed using Kaluza software ( aluza(R) Analysis Software, Beckman Co The analysis was performed using the ultra method.
[0253] (Plasmid transfection experiments and clone selection) Plasmids encoding various proteins were transfected into CHO cells using the Fugen kit. The stable clones were then transfected with Ge Selection using neticin and FACS, followed by Western blot or RT-PCR analysis was performed to identify the clone with the highest expression.
[0254] (Tissue Array) TissueScan Human Normal Tissue qPCR Arr ays (OriGene Technologies, Rockville MD) The expression of I5-13-sCD146 and I10-sCD146 was examined in 48 different tissues. The manufacturer's instructions were followed.
[0255] (ELISA) Shed sCD146 was assayed using a commercially available ELISA assay (CY-QUANT sCD1 46, Biocytex, Marseille) was used to evaluate the plate. Surface coated with heterologous mouse monoclonal anti-human CD146 F(ab')2 fragment 10 μL of serum was added to each well and incubated for 30 minutes at room temperature. After incubation, the plate was washed five times and incubated with a specific HRP-conjugated monoclonal antibody ( 7A4-HRP,1mg / ml,Biocytex,Marseille,France ) at a dilution of 1:1000 in specific diluent for 30 minutes at room temperature. Then, the plate was washed five times. 200 μL of tetramethylbenzidine (TMB) substrate was added at room temperature for approximately 2 The plate was incubated for 10 minutes. The color reaction was then initiated by adding 100 μL of acidic solution. The intensity of the signal correlated directly with the initial concentration of sCD146 in the sample. Closely related are two spliced isoforms of sCD146 (I5-13s The same immunoassay was used to detect I10-sCD146 and I10-sCD146. The protocol was modified to use HRP as the secondary antibody (detection antibody) only. To displace the anti-I5-13-sCD146 or anti-I10-sCD146 antibodies that bind to was changed to.
[0256] (Measurement of endothelial permeability) ECFCs were cultured in a 24-multiwell double-chamber system (Multiwell l Insert System, BD Biosciences, Le Pont d 6 per well (1 μm pores) on a membrane insert (Eclairix, France) 0,000 cells were seeded with or without siRNA transfection. Confluent endothelial monolayers were incubated in EGM-2 medium for 24 hours to detect the presence of various forms of sCD146. FITC-dextran (Sigma) was added to the apical surface of the cells. The cells were allowed to migrate for 1.5 hours at 37°C. -Dextran was stained with Cytofluor Series 4000 Fluoresce (PerSeptiveBiosystems, Framingham, MA) was used and measured.
[0257] (Immunofluorescence experiment) The localization of various isoforms of CD146 and ADAM10 / Tace was examined using coverslips. The cells were fixed with paraformaldehyde for 10 min at room temperature. Then, the cells were permeabilized with saponin (0.2%) and then incubated with anti-CD146 antibody for 30 min at room temperature. (1 / 100) and anti-Tace (1 / 200) or anti-ADAM10 (1 / 100) antibodies The cells were then incubated with a secondary antibody associated with a fluorescent probe. In some experiments, nuclei were stained with DAPI. Cells were then imaged under a confocal microscope ( Measured using a Zeiss 510.
[0258] In sections of muscle from ischemic mice, angiogenesis was induced by isolectin B4 (Life Technologies, Inc. The tissue sections were visualized using a fluorescent microscope (L echnologies, 1 / 100). The results were analyzed using a Leica sp5 (Leica, Nanterre, France).
[0259] (Histological analysis) The chorioallantoic membrane (CAM) of the chick embryo assay was surgically removed and resuspended in 10% buffered formaldehyde. The sections were fixed in ethanol for 10 hours, dehydrated in graded alcohols, cleared in xylene, and embedded in paraffin. Sections of 5 μm thickness were cut in a plane parallel to the surface of the CAM and observed under an optical microscope. The sections were stained with hematoxylin and eosin.
[0260] (Induction of hind limb ischemia in mice) Unilateral hindlimb ischemia was induced in female mice by complete resection of the entire left femoral artery. After surgery, animals were divided into four treatment groups: PBS in the ischemic adductor muscle once every 2 weeks for 28 days; One control group was injected with various recombinant human soluble CD146 (r h-sCD146, rh-I15-13-sCD146, rh-I10-sCD146) The subjects were divided into three experimental groups, treated with 0.01 mg / kg or 0.2 mg / kg.
[0261] (Laser Doppler blood flow analysis) The ratio of ischemic to normal hindlimb blood flow was measured using a laser Doppler flow analyzer. At various time points after surgery (1, 3, 7, 14, 21, and 28 days), the animals were The area of interest (legs and feet) was scanned three times in succession by laser. Blood flow was assessed in ischemic hind limbs versus normal. The results were expressed as the ratio of the normal hind limb to the normal hind limb.
[0262] (Research on angiographic CT images) The animals were then treated with a mixture of ketamine and xylazine (100 mg / kg each). The animals were deeply anesthetized with 2 mg / kg and 10 mg / kg of lipiodole. The CT 3D images were recorded with the following characteristics: 70 kVp energy, exposure MicroPET / microCT rodent with 300ms duration and 720 projections Acquire and quantify using an animal model scanner (nanoPET / CT, Mediso) Ta.
[0263] (subject) Sera from 24 SSc patients admitted to the Department of Internal Medicine in Marseille (France) were analyzed. All patients met the 2013 ACR / EULAR scleroderma classification criteria and As a control, the inventors conducted a randomized controlled trial of 24-year-olds, Sera from matched blood donors were investigated. All samples were The samples were from a designated Biobank (DC 2012-1704) and were stored at -8 Stored at 0°C.
[0264] (Ethics Committee Approval) Animal testing was conducted in accordance with Directive 2010 / 63 / EU of the European Parliament and is The above procedures have been approved by the Clinical Trials Committee (Aix-Marseille University). The study was conducted under the animal use protocol of the Marseille Ethics Committee and by an accredited researcher (B. Guille The work was carried out under the supervision of the International Federation of Commerce and Industry (FCOI) No. 13328.
[0265] The human sample studies were performed retrospectively on plasma from patients with systemic sclerosis. The study was conducted in accordance with the 1975 Declaration of Helsinki, as revised in 1983, and has been reviewed by relevant institutions. The study was approved by the committee and informed consent was obtained from the patients. B. Granel and N. Bardin analyzed the data, and all authors used the primary clinical data. .
[0266] (peptides, plasmids, antibodies, inhibitors) Recombinant human soluble form of shed sCD146 (rh-sCD146) CD146 was obtained from Biocytex. rh-I5-13-sCD146 and rh- I10-sCD146 is a protein column tagged with HA peptide (Trial The antibody was purified using the MBL Kit 3320A.
[0267] The plasmid encoding Tace was kindly provided by Dr F. Peiretti, UMR-S106 2,From Marseille, France.
[0268] The plasmid encoding ADAM10 was kindly provided by Dr. B. Charreau, UMR-S1 064, Nantes, France. I5-13-sCD146 and Polyclonal antibody against I10-sCD146 was obtained from Covalab company However, two proteins [NH2-C-YLDGPLPTPVDNPR-CON H2 (SEQ ID NO: 101) and NH2-C-RDQVTPSGVVFKLFDKKP-CO By injecting a peptide corresponding to a specific site of the NH2 (SEQ ID NO: 102), ADAM-17 (ab2051), ADAM-10 (EPR5622 ), CD146 (clone 7A4) andactine antibody , Abcam, Millipore, Biocytex and Cell, respectively. It was purchased from signaling.
[0269] GM6001 is from Selleck chemicals.
[0270] (statistical analysis) Data are expressed as the mean ± SEM of the indicated number of experiments. Statistical analysis was performed using the Prism software (GraphPad Software lnc., San Die The significance of differences was determined using the Mann-Whitney U test. A P value <0.05 was considered significant.
[0271] [result] (Various soluble CD146 variants were identified by the shedding of the membrane isoform of CD146. (generated by transcription and alternative splicing in endothelial cells) Secretion of soluble CD146 (sCD146) inhibits TNF, VEGF, and endothelial cell proliferation. It increased in response to various stimuli, including netrin, TGFb, and Wnt5a (Figure 21A). When TNF was produced more efficiently, the inventors found that sCD146 secretion was significantly higher than in control conditions. The study was performed in mice treated with pan-matrix metalloproteinase (PMP) and after treatment with TNF. In the absence or presence of the MMP inhibitor GM6001, shedding and splicing To estimate the relative contribution of the GM600 forms of sCD146, It was shown that the 1-dependent portion corresponds to 75% of the total secretion. % corresponds to GM6001-resistant secretions (FIG. 21B).
[0272] The inventors performed the same type of experiment in the presence of a furin convertase inhibitor (IF). The inventors found that IF was significantly higher in the control and TNF-dependent cells than in the control and TNF-dependent cells. Not surprisingly, in both conditions, the fraction of IF-resistant secretions was significantly increased. The minutes were the same (Figure 21C).
[0273] Finally, the inventors have investigated the effect of various tissue inhibitors of metalloproteinases (TIMPs) on the activation of sCD1. TIMP-1 (1 μg / ml) was used to inhibit 46 secretion (Figure 21D). ) was able to reduce the secretion of sCD146 in both conditions, whereas TIMP-3 (1 μg / ml) reduced sCD146 secretion only when cells were treated with TNF. This indicates that TIMP-2 (1 μg / ml) had no effect.
[0274] In summary, this experiment demonstrates that two different mechanisms of shedding, sCD146 and sCD146, are involved in the regulation of IL-1 expression. From the long sCD146, it is involved in the generation of sCD146, 2 / GM6001 The remaining fraction of resistant sCD146 secretions (approximately 25%) was sCD146 variant The production of β-terminal β-terminal ribosomal RNA occurs by alternative splicing of the primary transcript, and thus depends on a different mechanism. Show that you get it.
[0275] The long CD146 isoform mediates ADAM-10-dependent shedding of soluble CD146. (Produced in endothelial cells by stimulation with The inventors found that in control conditions, long (lgC) expression of sCD146 in endothelial cells was significantly increased. D146 siRNA) and short (shCD146 siRNA) CD146 siRNA The inventors analyzed the effect of lgCD146 siRNA on sCD146 secretion by approximately We observed that shCD146 siRNA had no effect, whereas shCD146 siRNA reduced the expression of IL-1 by 75% ( (Figure 22A) This indicates that in control conditions, only the long CD146 isoform was expressed by the shed This indicates that sCD146 secretion is involved in the sCD146 binding process. Considering the inhibitory effect of TIMPs on 146 secretion (the effect of TIMP-1), the inventors We tested the effects of siRNA targeting ADAM10, MT1-MMP, and MMP-2. The effect of siRNA targeting Tace was also tested as a control. B) Only ADAM10 siRNA can inhibit sCD146 secretion. The effect of was similar to that of GM6001.
[0276] To confirm this result, the inventors performed co-immunoprecipitation experiments and, under control conditions, lgCD146 co-immunoprecipitated with ADAM10, and shCD146 and ADAM10 were By immunofluorescence, the inventors demonstrated that l gCD146 is expressed in both endothelial cell junctions and perinuclear regions on confluent ECFCs. We showed that ADAM10 colocalizes with IL-1 in the intracellular compartment of confluent cells. The colocalization of lgCD146 and ADAM10 in the cell junctions of confluent cells Colocalization in the endothelial cell lineage was confirmed in another endothelial cell type, HUVEC. hCD146 did not colocalize with ADAM10 in confluent cells.
[0277] To assess whether the long and short forms of CD146 are complementary to each other, To investigate the mechanism of IL-146 expression, the inventors silenced lgCD146 with siRNA and investigated the expression of other forms of IL-146. Even when lgCD146 expression was suppressed, shCD146 mRNA expression was not observed. This confirmed the different localization of the two isoforms in endothelial cells. The inventors also determined that the mRNA expression of the two CD146 isoforms correlates well with AD. The effects of ADAM10 expression suppression or overexpression were analyzed. Overexpression did not alter the mRNA expression of either long or short CD146.
[0278] Since lgCD146 is expressed essentially at the junctions, the inventors hypothesized that it may be possible to induce AD in cells. The expression suppression and overexpression by AM10 were examined by cell permeability and dextran permeability. The results showed that ADAM10 si ECF using transfection of cells with RNA or ADAM10 plasmid C treatment increased or decreased the permeability to dextran, respectively, and Tace Treatment with siRNA or transfection with Tace plasmid increased the transmission The potential contribution of ADAM10 independent of CD146 cleavage To assess this, we performed a multicenter study in the presence or absence of long CD146 siRNA. We performed a permeability experiment to compare the effect of ADAM10 overexpression in endothelial cells. The results showed that ADAM10 overexpression and long CD146 siRNA transfection The results show that the endothelial permeability was significantly increased by the administration of long CD146 siRNA and overexpression in the cells. When transfected with ADAM10, the effect on permeability was longer than that of CD14. The effect was not significantly different from that observed when siRNA No. 6 was present alone. This suggests that ADAM10 essentially regulates permeability in such cells. , suggesting that it acts on long CD146.
[0279] To confirm this result, the inventors performed a study in CHO cells (which do not express CD146). The lgCD146 isoform was expressed by transfection with a plasmid containing this isoform. The expression of lgCD146 was achieved by transfecting the vector. The clone was selected. A plasmid encoding ADAM10 was transiently transfected into this clone. The effect of transfection on sCD146 secretion was observed. It is shown that sCD146 secretion was significantly increased in the presence of ADAM10. The effect of ADAM10 transfection was examined using lgCD146 (CHO- lgCD146 and CHO-C) were stably transfected or The permeability of CHO that was not infected was observed. The results showed that the permeability of CHO-lgCD146 was A In the presence of DAM10, the expression of ADAM10 was significantly increased in CHO-C cells. 10 was shown to have no effect.
[0280] In summary, this study demonstrated that endothelial cells express long CD146 at the junctions. is shed by ADAM10 to generate sCD146.
[0281] (Short CD146 isoforms are involved in Tace-dependent shedding in endothelial cells. (which produces soluble CD146) The inventors showed that the secretion of sCD146 after 24 hours of treatment with 20 ng / ml of TNF Long (lgCD146 siRNA) and short (shCD146 siRNA) CD14 The effects of 6 siRNA were analyzed in comparison with the control condition. We confirmed that only lgCD146 siRNA reduced sCD146 secretion (Figure 1). 23A) In the presence of TNF, both lgCD146 and shCD146 siRNAs suppressed the expression of sCD146. The inventors observed that the secretion of 146 was reduced by approximately 60% and 25%, respectively. Therefore, we used various siRNAs to detect the proteins required for shCD146 shedding. The effect of TIMPs on sCD146 secretion under TNF-induced oxidative stress (TIMPs) was investigated. In view of the inhibition by ADAM10, MT1-M The effects of siRNA targeting MP and Tace were examined. The results (Figure 23B) showed that AD When AM10 siRNA and Tace siRNA were added simultaneously, the effects were additive. Interestingly, ADAM1 can inhibit sCD146 secretion. 10 and Tace siRNA inhibited sCD146 secretion, while lgCD146 and shCD1 As observed with 46 siRNA, the reduction was 60% and 25%, respectively. The results showed that when lgCD146 was shedding by ADAM10, shCD146 It was suggested that this could be shed by Tace.
[0282] To confirm this hypothesis, we performed co-immunoprecipitation experiments and found that shC D146 co-immunoprecipitated with Tace, whereas lgCD146 co-immunoprecipitated with ADAM10. By immunofluorescence, the inventors demonstrated that shCD146 co-precipitated TN F: We showed that it colocalized with Tace in ECFC cells. shCD146 colocalizes with Tace at the membrane and in the nucleus, whereas in non-confluent cells In essence, lgCD14 colocalizes around the nucleus in the membrane folds of migrating cells. 6 did not colocalize with Tace in confluent cells. As shown in the previous study, silencing shCD146 expression significantly reduced lgCD146 mRNA expression. The results showed that the isoforms were not complementary to each other. also reported that Tace downregulates the mRNA expression of two CD146 isoforms. The effect of Tace on the expression of long or short CD146 was analyzed. None of them altered mRNA expression.
[0283] shCD146 has recently been described to be present in lipid rafts in endothelial cells and is ce was also described to be present in this cell fraction, so the inventors performed a control condition and a TNF The lipid raft fraction of ECFCs was analyzed. was added to the cells to avoid shedding of molecules. The results showed that in the control condition, s Figure 2 shows that hCD146 was not observed in lipid rafts. In contrast, under TNF Both shCD146 and Tace were present in this cell fraction. To this end, the inventors expressed the shCD146 isoform in CHO cells and shCD146 was expressed by transfecting a plasmid containing A stable clone was selected that expressed Tace in sufficient amounts. The effect of transfection on the secretion of sCD146 was observed. The results showed that in the presence of Tace, secretion of sCD146 was significantly increased. In summary, this study demonstrated that short CD146 is involved in the regulation of Tace expression in endothelial cells. It has been shown that sCD146 is shed and produced in inflammatory conditions (TNF).
[0284] Two novel soluble forms of CD146 generated by alternative splicing in endothelial cells Identifying new variants The inventors have demonstrated that a fraction of sCD146 secreted is GM6001-insensitive and thus Since we observed that this was independent of shedding of membrane-type CD146 (see Figure 21), The fraction contains alternative forms of sCD146 generated by alternative splicing of the primary transcript. To test this hypothesis, the inventors performed a 3D ECFC RNA sequencing was performed on cells. The results showed that at least two distinct isoforms of sC One of these isoforms is located in intron 10 of the molecule (I10 -sCD146 isoform). The other contained introns 5 and 1 of the molecule. 3 (I5-13-sCD146 isoform). A schematic diagram of the two isoforms compared to the shed form is shown. SEQ ID NO: 9 / 20 are the sequences of these isoforms (I5-13 and I10, respectively). Shows.
[0285] The inventors have demonstrated that I10-sCD146 and I10-sCD146 in ECFCs and other endothelial cells, as well as in HUVECs. The results demonstrated that both transcripts were expressed in ECFCs. and HUVEC (Fig. 24B), and immunofluorescence analysis of ECFCs and It was found to be expressed as a protein, as evidenced by Western blot analysis of the supernatant. The inventors demonstrated that the mRNA expression of the two splice variants of membrane CD146 We tested the effects of various stimuli that actually affect the shedding of the brain (see Figure 21A). Interestingly, they are differentially regulated. Indeed, I5-13sCD146 is a member of the CD146 is upregulated by TNF and Wnt5a at the NA level and shed form However, changes caused by VEGF, TGFb, netrin, and Wnt3a were not observed. I10-sCD146 was not upregulated by these factors at the mRNA level. The mRNA levels of the I10-sCD146 variant were significantly higher than those of VEGF, netrin, and Wnt3. It was even down-regulated by a (Figure 24C).
[0286] The relationship between this new splicing variant and the expression of other CD146 isoforms To evaluate the interaction, we performed siRNA experiments. Both 146 siRNA and short CD146 siRNA inhibited the expression of CD146 at the mRNA level. The results showed that the expression of I10-sCD146 or I5-13-sCD146 was not affected by the Similarly, siRNA against I10-sCD146 or I5-13-sCD146 The recombinant CD146 mRNA expression was not altered by the recombinant CD146 short or long mRNA expression. I10-sCD146 or I5-13-sCD146 protein enhances endothelial cell proliferation Treatment consisted of short CD146, long CD146, I5-13-sCD146 and I10-sC The data did not affect the mRNA level of D146. However, this supports the idea that they are not mutually complementary.
[0287] Taken together, this experiment demonstrates that in addition to shedding of membrane CD146 isoforms, sC D146 is also produced as two new splice variants of the primary transcript. show.
[0288] (Soluble CD14 in I5-13-sCD146 and I10-sCD146 isoforms) 6 exhibits proangiogenic effects in vitro and in vivo Because ECFCs constitute a useful model for studying ex vivo angiogenesis, the inventors Two spliced sCD146 isoforms (I10-sCD146) were expressed in ECFCs. The effect of GM6001 on the proliferation and proliferation of IL-13 (CD146 and I5-13-sCD146) was evaluated. In its presence, it prevents membrane CD146 shedding, thus preventing the release of this novel isoform The results showed that the siRNA targeted I10-sCD 146 and I5-13-sCD146 inhibited ECFC proliferation (Figure 25A). The efficiency of both siRNAs was demonstrated. Smids were also transfected into ECFCs to examine their effects on proliferation. The results (Figure 25B) show that both plasmids significantly increased proliferation. The angiogenic potential of the sCD146 isoform was also investigated using recombinant protein Recombinant I10-sCD146 and I5-13-sCD146 were generated and evaluated. Proteins (rh-I10-sCD146 and rh-I5-13-sCD146, respectively) The effect of the recombinant IgG on the proliferation of ECFCs was examined. The results were compared with those of the preshed sCD146 form (rh-sCD146) (Figure 25C ).
[0289] The results are shown in Table 1. Even though CD146 appears to reduce the efficacy of rh-I5-13-sCD146 , and increased endothelial cell proliferation. It also increased angiogenesis in the chorioallantoic membrane assay. (Figure 25D). The inventors performed 3D capillary tube formation experiments (sphere experiments) using three replicas. The results showed that the three recombinant proteins were Increased ability to generate capillaries, as measured by sprout number and cumulative sprout length ( Figure 25E) shows the effect of I5-13-sCD146 on shed Compared with sCD146 or I10-sCD146, it appears to be decreased. The pro-angiogenic properties of sCD146 in the form of sCD146 allowed the inventors to demonstrate the potent angiogenic properties in a mouse model of hindlimb ischemia. We decided to investigate the angiogenic effects of rh sCD on ischemic mice twice a week. 146, rh-I10-sCD146, rh-I5-13-sCD146 and VEGF2 The subjects were treated with 1 μg of DMSO for 28 days, and blood flow was estimated by laser Doppler imaging. The results showed that the three foams were able to increase blood flow compared to PBS-treated animals. The effects observed with various forms of sCD146, together with VEGF, The effect of I1 was much higher than that observed in the control group (Figure 26A). The effect of 0-sCD146 was significant as soon as 3 days after the first injection. The kinetics of the oxidative stress response in muscle cells was faster than that of other molecules. The angiogenesis was associated with rh-I10-sCD146, rh-I5-13-sCD146, and In animals treated with h-sCD146 and VEGF, the mean age was 18.1 years compared to PBS-treated control animals. Finally, angiographic images showed that rh-I10 increased the vascular endothelial function compared to rh-I10 (Fig. 26B). -sCD146, rh-I5-13-sCD146 and rh -sCD146 The number of blood vessels in the legs was also increased compared to the PBS-treated legs (Figure 26C). Quantification was performed using rh-sCD146, rh-I10-sCD146, and rh -I5-13-sCD146 and VEGF treatment in the calf, thigh and whole leg In all experiments, I10-sCD146 and shCD146 were significantly increased. ed-sCD146 showed higher efficacy than I5-13-sCD146. Shedding of the long CD146 isoform by ADAM10 is a transendothelial Since this is associated with increased transmission of the new splatter (see FIG. 22), the inventors The isoform variants I10-sCD146 and I5-13-sCD146 altered this permeability. The results showed that siRNA transfection also overcomes this barrier. Treatment with recombinant proteins corresponding to the inhibitors did not alter transendothelial permeability. This indicates that
[0290] Taken together, these results suggest that both shed forms of sCD146 and splice variants Ant has been shown to have angiogenesis-promoting effects as a VEGF. 146 and shed sCD146 showed even greater angiogenesis-promoting effects than I5-13-sCD146. Compared to CD146, it appears to be
[0291] (I5-13-sCD146 and I10-sCD146 showed differential effects on fibrosis. , differentially regulated in systemic sclerosis) The inventors analyzed the mRNA levels of the newly identified sCD146 variants using tissue arrays. The results are shown in Figure 28. On the other hand, many organs were analyzed using I5-13-sC. Although no tumors expressed D146 or I10-sCD146, no tumors expressed lung, lymph node, or rectum. Interestingly, peripheral blood lymphocytes highly expressed the isoform sCD146. The mice expressed I5-13-sCD146 at high levels, but I10-sCD146 did not. I5-13-sCD146 and I10-sCD146 were highly expressed in the lung and were associated with TN Since the IL-11 deficiency is differentially regulated by F and Wnt5a / 3a, the inventors have demonstrated that IL-11 deficiency is a pathological event in systemic sclerosis (S We decided to focus on the expression of this isoform in Sc.
[0292] The inventors therefore found that shed sCD146, I5-13 in the serum of SSc patients. The concentrations of I10-sCD146 and I10-sCD146 in patients with IL-10 were determined in comparison with control patients (Figure 1 27A). The results showed that shed sCD146 and I5-13-sCD146 significantly increased the expression of SSc. showed that I10-sCD146 was significantly increased in patients with glaucoma, whereas I10-sCD146 was decreased. Interestingly, the inventors found that I5-13-sCD146 concentrations were significantly higher in the blood of patients with pulmonary fibrosis. In patients with pulmonary disease, the pulmonary function was significantly increased compared to those without pulmonary disease (inset). ).
[0293] Recently, the inventors have demonstrated that the canonical Wnt pathway, which is involved in fibrosis in SSc, is downregulated by sCD146. reported that the IL-1 gene is regulated by IL-1 in mouse embryos (Kaspi et al., 2017). Various soluble phosphatase inhibitors in a model of b-catenin / TCF transcriptional activity in fibroblasts (MEFs) We first analyzed the effect of the CD146KO mice on the proliferation of wild-type MEFs. showed that MEFs derived from mice were more sensitive to bleomycin than MEFs derived from mice (Figure 27B, left Therefore, MEFs from CD146KO mice were shed sCD146, I1 The effects of 0-sCD146 and I5-13-sCD146 were analyzed. (FIG. 27B, right part) shows that sCD146 and I10-sCD146 inhibited b-catenin / I5-13-sCD146 decreased TCF transcription activity, whereas I5-13-sCD146 increased it. showed.
[0294] In the mechanism, the inventors investigated the mechanism of action of bleomycin-induced systemic sclerosis in an animal model. (Kaspi et al., 2017) was used. Bleomycin-treated animals were then treated with shed sCD146, I5-13-sCD146 or I10-sCD146 were subcutaneously injected. The skin thickness, skin surface area and blood vessel density were then analyzed. Treatment with sCD146 or I10-sCD146 increased skin thickness. Treatment with I5 reduced this skin thickness to the values observed in control animals. There was no significant effect of -13-sCD146 (Figure 27C). Reduced tube formation was observed macroscopically in bleomycin-treated animals. Treatment with shed sCD146 and I10-sCD146 significantly This leads to an increase in angiogenesis observed at the microscopic level, whereas I5-13-sCD1 Treatment with 46 did not. This result was confirmed after labeling with isolectin-b4. Vascular density was reduced in bleomycin-treated animals, and this effect was associated with increased expression of sCD1. 46 and I10-sCD146 significantly regressed the IL-16 expression. In contrast, I5-13-sCD1 46 had no effect (Figure 27E).
[0295] Taken together, these results suggest that I5-13-sCD146 is profibrotic and inhibits pulmonary fibrosis. In contrast, I10-s was highly increased in the serum of SSc patients with glaucoma. CD146 and shed sCD146 are antifibrotic and in animal models of SSc. This can reduce fibrosis caused by
[0296] [Consideration] In this study, the inventors demonstrated that multiple isoforms of sCD146 are expressed by endothelial cells. For the first time, the inventors demonstrated that both membrane CD14 Identify the proteolytic enzymes involved in shedding of the six isoforms and characterize the primary transcripts It is generated by alternative splicing and encodes an additional sCD146 protein. reported the existence of two additional isoforms that are involved in angiogenesis and These molecules exhibit various properties that are relevant to the regulation of fibrosis and fibrosis. This fact highlights its importance in physiology and / or pathology. Various splice variants encode many proteins, particularly another highly proangiogenic molecule, V Soluble CD146 has also been identified in multiple splices. It is possible to constitute a large family of proteins with variants.
[0297] Regarding the shed form of CD146, the inventors identified the membrane CD146 isoform As a function, we have established that it is generated by two different ADAMs. In fact, the long form The short form is shedding by Tace, while the short form is shedding by ADAM10. Interestingly, the inventors found that the short isoform of CD146 inhibits the proliferation of Senilin 1 induces shedding of the extracellular portion and subsequent shedding of the intracellular portion. More completely proteolytically processed to generate the intracellular domain (shCD146-ICD) In contrast, the long isoform is only involved in extracellular shedding. We showed that the short CD146 isoform Thus, the nuclear translocation of shCD146-ICD may exert a direct transcriptional effect. In the current study, the inventors demonstrated that the ADAM involved in shCD146 Interestingly, Tace and presenilin 1 are proteins This is often associated with the development of continuous shedding of protein. In addition, these two molecules are processed to generate NICD through transcriptional effects ( Gudey et al., 2014).
[0298] In addition to the shed form of CD146, our study showed that endothelial cells We show that two other forms of sCD146 can be secreted. The genome is generated by alternative splicing. The first property we prove for the shed form is that Ouri K. et al., 2010), and the ability to promote angiogenesis. The results were observed as soon as 3 days after injection of the molecule into ischemic animals, so I10-sCD 146 and shed sCD146 showed rapid effects. The angiogenic potential of I10-sCD146 was higher than that of I10-sCD146. It has been shown to exist in various isoforms with angiogenic potential. The main angiogenic molecule, VEGF, exhibits multiple isoforms (Guyot M. et al., 2013). 15) This isoform is expressed in different cells and influences angiogenesis / lymphangiogenesis. The various receptors that can bind to the β-lactamases are shown in Fig. 1 (Jussila L. et al., 2002). Isoforms also bind the same receptor and express different signals to elicit different cellular outcomes. It induces signaling and transport in the endothelial cells (Fearnley GW et al., 2016). At least four different receptors, VEGF R1 / 2 / 3 and neuropilin 1, among others, are involved in the regulation of VEGF expression. This receptor is involved in lymphangiogenesis as well as angiogenesis. Further studies have investigated whether different sCD146 variants bind different receptors and whether they are involved in lymphatic It will be necessary to determine whether it also plays a role in angiogenesis. We described angiogenic isoforms of VEGF, which indicate that both types of molecules are expressed in tumors. However, they are not as effective as anti-V-cells, such as bevacizumab. It is inhibited by the EGF molecule, reducing the therapeutic effect (Biselli-Chicote PM et al., 2012). The inventors recently reported that soluble CD146 was expressed in clear cell renal cell carcinoma. constitute a predictive marker for sunitinib efficacy, and one of the mechanisms of resistance to sunitinib is differentiation. showed that it may depend on the enormous increase in offspring (Dufies M. et al., 2018 ) The alternative splice variant described in this study is proangiogenic, The contribution of this phenomenon will be analyzed. Another isoform of sCD146 is also involved in fibrosis, particularly in systemic sclerosis (SSc). SSc is characterized by severe fibrosis and dysregulated angiogenesis. Abnormalities in many factors have been reported (Hummers LK et al., In this study, the inventors identified the I5-13-sCD146 splice barrier The expression of Wnt5a and TNF was increased in the serum of SSc patients. The I10-sCD146 expression was significantly enhanced by Wnt3A and VEGF. The two observed in the serum of patients with SSc were The regulation of isoforms of TNF, Wnt3a and VEGFR1 in SSc patients has been described. This result is consistent with the increased F. This result supports the involvement of CD146 / sCD146 in SSc. This is important because it confirms that various proangiogenic forms of sCD146 We show that bleomycin-induced S in mice is regulated in pathological conditions. Using an in vivo model of Sc, the inventors demonstrated that shed sCD146 and I10-s CD146 can reduce SSc as determined by skin thickness, On the other hand, I5-13-sCD146 did not reduce SSc. Profoundly, shed sCD146 and I10-sCD146 were expressed in the dermal blood of this animal. I5-13sCD146 was able to increase tube density, whereas I5-13sCD146 did not. Thus, while all forms are proangiogenic, sCD146 and I10- Only sCD146 was able to stimulate the generation of new blood vessels in this model. This suggests that different forms of sCD146 can participate in different pathways, and This suggests that the effects of shed light are balanced depending on the pathological condition. sCD146 and I10-sCD146 also potentiated the expression of β-CD146 in an in vitro model of MEFs. It can also reduce -catenin / TCF transcriptional activity, downregulating the canonical Wnt pathway. This suggests a potential reduction in dermal fibrosis due to I5-13-sCD14. 6 increased it. This result clearly indicates that I5-13-sCD146 increased the sCD Compared with I10-sCD146 and I10-sCD146, it acts through various receptors and transmits various signals. Taken together, this data supports the idea that the IL-1 pathway may be activated. , I10-sCD146 and I5-13-sCD146 are novel biomarkers in SSc In particular, I5-13-sCD146 was shown to be a marker for SSc with pulmonary fibrosis. The fact that the levels of pulmonary fibrosis were significantly increased in patients with pulmonary fibrosis compared with those with pulmonary fibrosis is a marker of the severity of the pathology. Furthermore, shed sCD146 and I10-sCD146 were found to be fibroblast-specific. I5-13-sCD146 has therapeutic effects in SSc by increasing angiogenesis In conclusion, this study shows that the two membrane isoforms We identified two proteases involved in the shedding of the CD146 subunit and identified alternative splicing We identify two additional isoforms of sCD146 generated by cloning. All variants exhibit proangiogenic properties and promote vascular They appear to constitute a new family of pro-angiogenic molecules. are differentially regulated in the serum of patients with and display differential fibrotic properties.
[0299] Example 4 - Fibrosis in a mouse model of renal interstitial fibrosis induced by dietary adenine Inhibitory effect of sCD146-specific antibodies on the development of inflammatory bowel disease The inventors have demonstrated that the use of dietary adenine reduces the risk of developing chronic kidney disease associated with interstitial fibrosis. This induces crystalline nephropathy that progresses to tubulointerstitial fibrosis. C57 BL / 6 mice were 8 weeks old and were conditioned with 0.25% adenine (A04 Ade 0.25% Control mice were fed a diet containing A04, Safe for 12 days. After 12 days, the diet was stopped and the animals were either immediately or one week after the end of the diet. , for 2 or 3 weeks.
[0300] The results showed that 2 weeks after the end of the adenine diet, the animals showed interstitial renal fibrosis, In contrast, control animals had no fibrosis (Fig. 33A). This was accompanied by increases in TGFb, collagen 1a, and aSMA, as observed in (Figure 33B). aSMA protein was also significantly increased (Figure 33C). They found a progressive increase in CD146 mRNA expression that was significant after the end of the adenine diet. The results were observed at 2 and 3 weeks (FIG. 33D). treated animals IV with 10 μg of anti-sCD146 antibody twice a week from the start of the adenine diet. The mice were treated once and sacrificed two weeks after the end of the diet. Interestingly, animals treated with anti-sCD1 also developed extensive fibrosis. Animals treated with antibody 46 showed a significant reduction in interstitial fibrosis (Figure 34A and Figure 34B).
Claims
1. In detecting a predisposition to, diagnosing and / or predicting the prognosis of, or monitoring cardiac or renal fibrosis in a subject SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4 for use as biomarkers in 4. A soluble CD146 protein selected from SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 。
2. The present invention relates to a method for the detection, diagnosis, prognosis, or monitoring of a predisposition to fibrosis in a subject. I5-13 soluble CD146 protein or sequence of SEQ ID NO: 8 for use as a marker Row number 9, I10 soluble CD146 protein.
3. Detecting or diagnosing a predisposition to cardiac or renal fibrosis in a subject in vitro or ex vivo and / or Or a method for predicting prognosis, comprising: The method further comprises detecting expression of the soluble CD146 protein in a biological sample from the subject. determining a level of soluble CD146 protein, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7 How to do it.
4. The method comprises: determining the expression level of said soluble CD146 protein in said subject's biological sample; wherein the soluble CD146 protein is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, A step selected from sequence number 3, sequence number 4, sequence number 5, sequence number 6, and sequence number 7 i) and ii) comparing the expression level determined in step i) with a reference value; 、 If the level determined in step i) is higher than the reference value, the subject It is concluded that the patient has a predisposition to fibrosis, is affected by fibrosis, or has a poor prognosis. or if the level determined in step i) is lower than the reference value, the patient , not having a predisposition to fibrosis, not being affected by fibrosis or having a good prognosis and iii) concluding that:
5. Detecting or diagnosing a predisposition to fibrosis in a subject, in vitro or ex vivo, and / or A method for predicting a prognosis, comprising: The method comprises the step of: The expression level of soluble CD146 protein in the biological sample of the subject is measured. determining whether the first parameter is greater than the second parameter;
6. The method comprises: The I5-13 soluble CD146 protein expression level is measured in a biological sample from the subject. i) determining ii) comparing the expression level determined in step i) with a reference value; The subject is predisposed to, affected by, or has a poor prognosis for fibrosis. and concluding if said level determined in step i) is higher than said reference value; or The patient is not predisposed to fibrosis, is not affected by fibrosis, or has a good prognosis. If the level determined in step i) is lower than the reference value, and iii) selecting a first stimulant for detecting a first stimulant.
7. The method comprises: The I10-soluble CD146 protein expression level is measured in a biological sample from the subject. i) determining ii) comparing the expression level determined in step i) with a reference value; The subject is predisposed to, affected by, or has a poor prognosis for fibrosis. Then, if the level determined in step i) is lower than the reference value, conclude or the patient is not predisposed to, not affected by or at risk of developing fibrosis. If the level determined in step i) is higher than the reference value, the result is and (iii) reasoning about the difference.
8. Methods for monitoring cardiac or renal fibrosis in a subject, in vitro or ex vivo There was, The expression level of the soluble CD146 protein is determined in a biological sample of the subject. At the above time points, the soluble CD146 protein is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 A determining step is included, A time point when the expression level of soluble CD146 protein is late in the biological sample of the subject. and the higher level is indicative of a baseline value obtained at an earlier time point in the subject's biological sample. The subject exhibits increased fibrosis while exhibiting low levels of soluble CD146 protein. This indicates a reduction in fibrosis, and equal soluble CD146 protein levels indicate a reduction in fibrosis. The method of monitoring indicates that the disease is not progressing in the subject.
9. 1. A method for monitoring fibrosis in a subject in vitro or ex vivo, comprising administering to a subject a nucleic acid sequence selected from the group consisting of SEQ ID NO:8 The expression level of the I5-13 soluble CD146 protein is measured in a biological sample from the subject. The expression level of soluble CD146 protein is determined at two or more time points in the At a time point when the signal is slow in the biological sample of the subject, and a higher value relative to a baseline value obtained at an earlier time point indicates increased fibrosis in the subject. On the other hand, low levels of human soluble CD146 protein indicate reduced fibrosis. However, equal human soluble CD146 protein levels are associated with increased risk of fibrosis in the subject. A monitoring method to show that
10. 1. A method for monitoring fibrosis in a subject in vitro or ex vivo, comprising administering to a subject a nucleic acid sequence comprising SEQ ID NO:9 The expression level of the I10 soluble CD146 protein is measured in a biological sample of the subject. determining at least one of the two or more time points the amount of soluble C in the subject's biological sample; The expression level of D146 protein is detected in a biological sample from said subject at a later time point. A lower value relative to a baseline value obtained at an earlier time point indicates increased fibrosis in the subject. On the other hand, high levels of human soluble CD146 protein indicate reduced fibrosis. The equal levels of human soluble CD146 protein indicate that fibrosis is progressing in the subject. A method of monitoring that indicates when a problem is not occurring.
11. A subject, typically predisposed to fibrosis, affected by fibrosis, or with a poor prognosis. A subject identified as having fibrosis by the method of claim 3 or 4, or a subject with non-progressing fibrosis. In a subject identified by the method of claim 8 as having increased fibrosis or fibrosis. SEQ ID NO: 1, SEQ ID NO: 2, for use in the prevention or treatment of cardiac and / or renal fibrosis. SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 An inhibitor of soluble CD146 protein.
12. A subject, typically having a predisposition to fibrosis, being affected by fibrosis or having a poor prognosis. A subject identified by the method of claim 5 or 6 as having fibrosis of or without progression of fibrosis. In a subject identified by the method of claim 9 as having increased fibrosis or fibrosis. The I5-13 soluble CD14 of SEQ ID NO: 8 for use in the prevention or treatment of fibrosis 6 protein inhibitors.
13. The inhibitor is selected from an antibody, an aptamer, a polypeptide, a small organic molecule, and a nucleic acid. the soluble CD146 inhibitor according to claim 11 or the I5-13 soluble CD146 inhibitor according to claim 12 Soluble CD146 inhibitor.
14. The inhibitor is an anti-CD146 monoclonal antibody, preferably a soluble form of CD146. The soluble C antibody according to any one of claims 11 to 13, which is a monoclonal antibody that specifically binds to D146 inhibitor.
15. SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO: 7 and an inhibitor of a soluble CD146 protein selected from the group consisting of: or a pharma- ceutically acceptable carrier for use in the prevention or treatment of renal fibrosis. A composition comprising:
16. Inhibitor of the I5-13 soluble CD146 protein of SEQ ID NO: 8 and and a pharma- ceutically acceptable carrier for use in the prevention or treatment of fibrosis.
17. The soluble CD146 protein according to claim 1, and the I5-13 according to claim 2. A soluble CD146 protein or said I10-soluble CD146 protein, Detecting or determining a predisposition to cardiac or renal fibrosis in vitro or ex vivo according to 3 or 4. A method for diagnosing and / or predicting the prognosis of an in vitro or a method for detecting or diagnosing and / or prognosing a predisposition to fibrosis ex vivo A method for monitoring cardiac or renal fibrosis in vitro or ex vivo according to claim 8, The method for monitoring fibrosis in vitro or ex vivo according to claim 9 or 10, The soluble CD146 inhibitor according to claim 11, 13 or 14, or the composition according to claim 15 or 16. The subject is a mammal, preferably a human. Methods for detecting or diagnosing and / or predicting the prognosis of cardiac or renal fibrosis, A method for monitoring fibrosis, or a soluble CD146 inhibitor or composition.
18. The I5-13 soluble CD146 protein or I10 soluble CD146 protein according to claim 2 6. Proteins according to claims 5 to 7 for detecting predisposition to fibrosis in vitro or ex vivo A method for diagnosing and / or predicting the prognosis of an in-vitro agent according to claim 9 or 10. A method for monitoring fibrosis in vivo or ex vivo, comprising administering to a subject a subject of claim 12, 13 or 14, 17. A soluble CD146 inhibitor according to claim 13, or a composition according to claim 16, wherein the fibrosis is pulmonary fibrosis. Detection or diagnosis of a soluble CD146 protein, a predisposition to fibrosis, and / or A method for predicting prognosis, a method for monitoring fibrosis, or a soluble CD146 inhibitor or composition.
19. SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO: 7, or the composition of SEQ ID NO:
9. I10 Soluble CD146 Protein and Methods for Treating Skin Fibrosis in a Subject, Preferably a Human and / or a pharma- ceutically acceptable carrier for use in the prevention or treatment of pulmonary fibrosis.
